

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 31/00, C07H 21/00, C07K 15/00, 15/28, C12N 1/19, 1/21, 5/10, 9/16, 15/55, C12Q 1/43		A1	(11) International Publication Number: WO 94/20079 (43) International Publication Date: 15 September 1994 (15.09.94)
(21) International Application Number: PCT/US94/02612 (22) International Filing Date: 10 March 1994 (10.03.94) (30) Priority Data: 08/029,334 10 March 1993 (10.03.93) US		(81) Designated States: JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With international search report.	
(71) Applicant (for all designated States except US): SMITHKLINE BECHAM CORPORATION [US/US]; Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): LIVI, George, P. [US/US]; 33 E. Langhorne Avenue, Havertown, PA 19083 (US). McLAUGHLIN, Megan, M. [US/US]; 2505 Mansfield Avenue, Drexel Hill, PA 19026 (US). TORPHY, Theodore, J. [US/US]; 421 Shortridge Drive, Wynnewood, PA 19096 (US). (74) Agents: JERVIS, Herbert, H. et al.; SmithKline Beecham Corporation, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).			

(54) Title: HUMAN BRAIN PHOSPHODIESTERASE

(57) Abstract

Isolated cDNA clones from human brain (frontal cortex) cDNA libraries that encode an unique subtype of the low K_m , cAMP-specific phosphodiesterases (PDE IVs) are disclosed. Analysis of the distribution of hPDE IV_B mRNA expression in various human tissues using a nonconserved fragment of the cDNA as a probe revealed a restricted pattern of expression, with an ~4-kb mRNA detected in brain, heart, lung and skeletal muscle and not in placenta, liver, kidney or pancreas. Furthermore, an additional ~5-kb hPDE IV_B related mRNA species was detected in brain tissue. Expression of hPDE IV_B in a genetically-engineered PDE-deficient strain of the yeast *Saccharomyces cerevisiae* resulted in the overproduction of cAMP PDE activity which displayed the expected kinetic characteristics for a PDE IV: (1) low K_m (4.3 μ M) for cAMP, (2) high K_m (>3 mM) for cGMP, and (3) sensitivity to rolipram (K_i = 0.085 μ M), a selective inhibitor of PDE IV. Recombinant hPDE IV_B also bound [³H]R-rolipram saturably and with a high affinity. Analysis of [³H]R-rolipram binding data revealed curvilinear Scatchard plots, suggesting the presence of two non-interacting high affinity rolipram binding sites (K_d = 0.4 and 6nM) or a negatively cooperative interaction among multiple binding sites. This novel enzyme is particularly useful for screening candidate compounds for their ability to serve as potential anti-depressant, antiasthmatic or anti-inflammatory agents.

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroun	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Larvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Human Brain Phosphodiesterase

Field of the Invention:

5 This invention relates to cDNAs encoding phosphodiesterases (PDEs), their use in the recombinant production of the enzyme and the use of the PDE in drug screening. More specifically this invention relates to a unique subtype of a human, low K_m , cAMP-specific phosphodiesterase (PDE IV) and its use in the screening of pharmaceutically useful substances.

10

Background of the Invention:

The recent identification and characterization of cDNA clones encoding several different mammalian PDEs has supported the cumulative biochemical evidence for the existence of multiple isozyme families as well as the number and 15 tissue distribution of particular subtypes (Livi, G.P. et al., Mol. Cell. Bio. 10:2678-86 (1990); Colicelli, J. et al., Proc. Natl. Acad. Sci. (USA) 86:3599-3603 (1989) and Davis et al., Proc. Natl. Acad. Sci. (USA) 86:3604-08 (1989)). A particularly interesting isozyme family with respect to drug discovery is the PDE IV family. There is considerable evidence to suggest that this isozyme family represents a 20 molecular target for a variety of therapeutic agents ranging from anti-depressants (Nicholson, C.D. et al., Trends in Pharm. Sci. 12:14-27 (1991)) to anti-asthmatic and anti-inflammatory agents (Torphy, T.J. and B.J. Undem, Thorax 46:512-23 (1991)). The cloning, expression and biochemical characteristics of hPDE IV_A, an enzyme encoded by a cDNA obtained from a human monocyte library has been 25 reported (Livi, G.P. et al. supra (1990) and Torphy T.J. et al., J. Biol. Chem. 267:1798-1804 (1992)). The purpose of this invention is to provide cloned and characterized PDE IV subtypes expressed in human brain.

Cyclic nucleotide phosphodiesterases (PDEs) consist of a family of enzymes that catalyze the hydrolysis of 3',5'-cyclic nucleotides, resulting in the formation of 30 5'-nucleotide metabolites. At least five distinct mammalian PDE isozyme families exist, each distinguished on the basis of a number of biochemical properties including 1) enzyme kinetics, 2) substrate selectivity, and 3) selective inhibition by various compounds. These isozyme families are defined as: I) the Ca^{2+} /calmodulin-dependent PDEs; II) the cGMP-stimulated PDEs; III) the cGMP-inhibited PDEs; IV) the cAMP-specific PDEs and V) the cGMP-specific PDEs 35 (Beavo, J.A. et al., Trends Pharmacol. Sci. 11:150-155 (1990) and Conti, M. et al., Endocrine Rev. 12:218-234 (1991)).

There is considerable interest in evaluating inhibitors of the low- K_m , cAMP-specific PDEs (PDE IVs) as potential anti-inflammatory and anti-asthmatic drugs. As mentioned above, the cloning and expression of a cDNA that encodes a human PDE IV subtype expressed in monocytes (hPDE IV_A) has been reported. This 5 enzyme exhibited significant amino acid sequence homology to PDE IVs from rat brain (Colicelli, *supra* (1989)) and *Drosophila* (Chen, C-N. et al. *Proc. Nat'l. Acad. Sci. USA* 83:9313-17 (1986)). Furthermore, the recombinant enzyme was overexpressed in both yeast and mammalian cells and defined as a PDE IV based on its kinetic characteristics and sensitivity to isozyme-selective inhibitors.

10 Recombinant hPDE IV_A possesses a low K_m for cAMP ($K_m = 3.2 \mu\text{M}$), a high K_m for cGMP, and is inhibited by rolipram ($K_i = 0.06 \mu\text{M}$) but not by selective inhibitors of other PDE isozymes.

It has been proposed that the anti-depressant activity of the PDE IV-selective inhibitor rolipram is associated with the inhibition of PDE IVs in the central nervous 15 system. Rolipram binds with high affinity to rat brain homogenates and it has been assumed that this binding site represents either a catalytic or allosteric site within the PDE IV molecule itself. Accordingly, it has been recently established that recombinant hPDE IV_A possesses both catalytic activity and a high affinity ($K_d = 2$ nM) [³H]-rolipram binding site (Torphy T.J. et al. *J. Biol. Chem.* 267:1798-1804 20 (1992)). Although the relationship between this high affinity binding site and the catalytic activity of hPDE IV_A is not clear, it has been proposed that this site may represent either an allosteric site or the catalytic site on one of two distinct catalytic forms of the enzyme. It is of considerable interest to know if an additional PDE IV subtype is expressed in human brain, and if so, whether this subtype has 25 biochemical characteristics similar to hPDE IV_A. Of particular interest is the determination whether the high affinity rolipram binding site exists on PDE IV subtypes in addition to hPDE IV_A.

Although the mechanism of action of rolipram can be assessed biochemically using the available recombinant PDE IV enzymes derived from human monocytes 30 and rat brain, a true pharmacological understanding of how PDE IV activity (as well as cellular cAMP content) regulates neurobiochemical processes is limited by lack of knowledge regarding PDE IV subtypes expressed in the human brain, if any. Accordingly, it is a purpose of this invention to provide isolated cDNA clones encoding PDE IV from human brain and to employ this valuable reagent in a 35 screening protocol for the discovery of subtype-specific PDE IV inhibitors. Disclosed herein is the cloning of a cDNA from a human frontal cortex cDNA library that encodes a unique PDE IV subtype. This enzyme is designated as hPDE

IV_B according to the nomenclature of Beavo and Reifsnyder *supra* (1990). The cDNA product is defined as a type IV PDE based on its comparative amino acid sequence as well as PDE IV-selective inhibitors, the kinetic characteristics and the [³H] rolipram binding capacity of the recombinant enzyme. Surprisingly, this PDE 5 IV_B subtype exhibits a restricted tissue-type pattern of expression.

Brief Description of the Invention

This invention provides an isolated nucleic acid molecule encoding a human PDE IV_B. This invention also provides a human PDE IV_B substantially free of other proteins of human origin. The invention also provides molecular reagents such as cloning and expression vectors for the recombinant production of the PDE IV_B enzyme. The invention also provides recombinant host cells capable of expressing the enzyme. The invention further includes a method for identifying ligands capable of binding to a PDE IV_B enzyme comprising: contacting a PDE IV_B 10 enzyme with a plurality of candidate ligands labeled with an analytically detectable reagent under conditions sufficient for ligand binding and identifying those ligand candidates capable of enzyme binding by detecting the presence of a labeled ligand/enzyme complex. The invention also provides a method of screening 15 compounds to identify those compounds which bind to a human PDE IV_B enzyme comprising contacting the enzyme with (a) a plurality of drug candidates in the presence of (b) an analytically detectable ligand known to bind to the enzyme, under 20 conditions that permit binding of (a) and (b) to the enzyme, and identifying those candidate compounds capable of enhancing or inhibiting the binding or interaction of the known ligand with the enzyme. The invention also provides for detecting 25 candidate compounds capable of inhibiting the catalytic activity of the enzyme by monitoring the effect of the compound on the ability of the enzyme to hydrolyze substrates (e.g., cAMP). The invention also provides biological screening assay for 30 the detection of PDE IV_B selective ligands comprising: (a) providing a PDE deficient host cell that exhibits a specific growth arrest phenotype associated with elevated cAMP levels; (b) transforming or transfecting said host cell with the 35 plasmid capable of directing the expression of a PDE IV_B enzyme and culturing the resultant recombinant host cell under conditions sufficient for the expression of PDE IV_B enzyme and sufficient to generate a growth arrest response should the expressed PDE IV_B enzyme be inhibited; (c) contacting the recombinant host cell with a plurality of candidate compounds and (d) identifying those compounds which are capable of inhibiting the enzyme and thereby unmasking the growth arrest phenotype. The invention also contemplates pharmaceutical compositions

comprising a compound identified by any of the three abovementioned methods and a pharmaceutically acceptable carrier. The invention further includes antisense oligonucleotides having sequence capable of binding specifically with any sequence of an mRNA molecule which encodes the human PDE IV_B so as to prevent the 5 translation thereof. The invention also provides antibodies directed to the human PDE IV_B. The invention also provides a fusion protein comprising a PDE IV_B domain and an cell surface localizing domain and a method of screening compounds to identify those compounds which bind to a human PDE IV_B enzyme comprising contacting recombinant host cells expressing on the surface thereof the fusion protein 10 with a plurality of drug candidates, under conditions to permit binding to the PDE IV_B domain, and identifying those candidate drugs capable of enhancing or inhibiting the catalytic activity of the enzyme.

Brief Description of the Figures

15 Fig. 1 illustrates the composite nucleotide sequence of the hb-PDE1a and hb-PDE1 cDNA clones with the predicted hPDE IV_B amino acid sequence. The entire coding sequence, as well as the complete 5' and 3'-UTRs, are shown. Coordinates at the right indicate nucleotide and amino acid positions. The amino acid sequence is shown starting from the putative translation initiation site (+1), and asterisks show 20 the putative termination codon. Upper case letters correspond to clone hb-PDE1, whereas lower case letters correspond to nucleotides unique to clone hb-PDE1a (see Examples). The underlined region represents a non-conserved region (see Fig. 2) that was used as a probe for the Northern analysis shown in Fig. 5A. The hb-PDE1 cDNA extends from positions -283 to 2363, whereas hb-PDE1a extends from 25 positions 1008 to 3609. The putative polyadenylation signal (5'-AATAAA-3') and poly (A) tract are bolded. The GenBank accession No. is M97515.

30 Fig. 2 illustrates the deduced amino acid sequence alignment of representative mammalian low-K_m cAMP-specific PDEs (PDE IVs). hPDE IV_B is the human brain PDE IV subtype reported here; hPDE IV_A is a human monocyte PDE IV; rPDE IV_A and rPDE IV_B represent two distinct rat brain PDE IVs derived from the cDNA clones RD1 and DPD, respectively. Dashes indicate identical amino acid sequences; periods indicate sequence gaps included to maximize alignments.

35 Fig. 3 illustrates the kinetics of hPDE IV_B cAMP hydrolysis and inhibition by rolipram. PDE activity was assessed in yeast lysates 6 hr after hPDE IV_B expression was induced. The data are representative of results from two separate

preparations. Panel A, double-reciprocal plot of cAMP hydrolysis. The concentrations of cAMP used ranged from 0.03 to 50 μ M. The K_m for cAMP was calculated to be $4.3 \pm 0.2 \mu$ M and the V_{max} was 11.3 nmol/mg protein/min. Data obtained with the 10 highest concentrations of cAMP are shown on an expanded scale in the inset. Panel B, analysis of the inhibitory effect of R-rolipram on cAMP hydrolysis by hPDE IV_B. The symbols represent the actual experimental data whereas the lines were generated from the KINPAC kinetic analysis program and represent the theoretical position of data points for a competitive inhibitor with a $K_i = 0.085 \mu$ M.

10

Fig. 4 illustrates Scatchard analysis of [³H] R-rolipram binding. Supernatant fractions of yeast cell lysates prepared 6 hr after induction of hPDE IV_B expression were incubated with various concentrations of [³H] R-rolipram (0.02-24 nM). Assays were conducted in the presence or absence of 1 μ M unlabeled rolipram to define saturable binding. The results shown represent a Scatchard analysis of saturable [³H] R-rolipram binding, which corresponded to more than 95% of the total binding. As analyzed by the Acufit computer program, the data best fitted a two-site model ($F<0.01$) with rolipram $K_{d1} = 0.4$ and 6 nM. The data are representative of the results obtained with two preparations.

20

Fig. 5 illustrates the human tissue distribution of hb-PDE1-specific mRNA. A Northern blot containing poly (A)⁺ mRNA extracted from various human tissues was probed with a ³²P-labeled PCR fragment of hb-PDE1 corresponding to a nonconserved 3' region (see Fig. 1) in Panel A, stripped, and reprobed with a ³²P-labeled β -actin cDNA in Panel B. Each lane contained 2 μ g of poly (A)⁺ RNA from the indicated human tissue. Size markers are in kb.

25

Detailed Description of the Invention:

In describing the present invention, the following terms will be employed, and are intended to be defined as indicated below.

An "antigen" refers to a molecule containing one or more epitopes that will stimulate a host's immune system to make a humoral and/or cellular antigen-specific response. The term is also used herein interchangeably with "immunogen."

The term "epitope" refers to the site on an antigen or hapten to which a specific antibody molecule binds. The term is also used herein interchangeably with "antigenic determinant" or "antigenic determinant site."

"Fusion protein" is a protein resulting from the expression of at least two operatively-linked heterologous coding sequences. The protein comprising a PDE IV_B peptide and a second unrelated peptide sequence is an example of a fusion protein.

5 A coding sequence is "operably linked to" another coding sequence when RNA polymerase will transcribe the two coding sequences into a single mRNA, which is then translated into a single polypeptide having amino acids derived from both coding sequences. The coding sequences need not be contiguous to one another so long as the expressed sequence is ultimately processed to produce 10 the desired protein.

10 "Recombinant" polypeptides refer to polypeptides produced by recombinant DNA techniques; i.e., produced from cells transformed by an exogenous DNA construct encoding the desired polypeptide. "Synthetic" polypeptides are those prepared by chemical synthesis.

15 A "replicon" is any genetic element (e.g., plasmid, chromosome, virus) that functions as an autonomous unit of DNA replication *in vivo*; i.e., capable of replication under its own control.

20 A "vector" is a replicon, such as a plasmid, phage, or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment.

25 A "double-stranded DNA molecule" refers to the polymeric form of deoxyribonucleotides (bases adenine, guanine, thymine, or cytosine) in a double-stranded helix, both relaxed and supercoiled. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, *inter alia*, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes. In discussing the structure of particular double-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand 30 of DNA (i.e., the strand having the sequence homologous to the mRNA).

A DNA "coding sequence of" or a "nucleotide sequence encoding" a particular protein, is a DNA sequence which is transcribed and translated into a polypeptide when placed under the control of appropriate regulatory sequences.

35 A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at the 3' terminus by a translation start codon (e.g., ATG) of a coding sequence and

extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site (conveniently defined by mapping with nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. Eukaryotic promoters will often, but not always, contain "TATA" boxes and "CAT" boxes. Prokaryotic promoters contain Shine-Dalgarno sequences in addition to the -10 and -35 consensus sequences.

5 DNA "control sequences" refers collectively to promoter sequences, 10 ribosome binding sites, polyadenylation signals, transcription termination sequences, upstream regulatory domains, enhancers, and the like, which collectively provide for the expression (i.e., the transcription and translation) of a coding sequence in a host cell.

15 A control sequence "directs the expression" of a coding sequence in a cell when RNA polymerase will bind the promoter sequence and transcribe the coding sequence into mRNA, which is then translated into the polypeptide encoded by the coding sequence.

20 A "host cell" is a cell which has been transformed or transfected, or is capable of transformation or transfection by an exogenous DNA sequence.

25 A cell has been "transformed" by exogenous DNA when such exogenous DNA has been introduced inside the cell membrane. Exogenous DNA may or may not be integrated (covalently linked) into chromosomal DNA making up the genome of the cell. In prokaryotes and yeasts, for example, the exogenous DNA may be maintained on an episomal element, such as a plasmid. With respect to eukaryotic cells, a stably transformed or transfected cell is one in which the exogenous DNA has become integrated into the chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cell containing the exogenous DNA.

30 A "clone" is a population of cells derived from a single cell or common ancestor by mitosis. A "cell line" is a clone of a primary cell that is capable of stable growth *in vitro* for many generations.

35 Two DNA or polypeptide sequences are "substantially homologous" or "substantially the same" when at least about 93% (preferably at least about 95%, and most preferably at least about 98%) of the nucleotides or amino acids match over a defined length of the molecule, normally the entire length of the molecule. As used herein, substantially homologous also refers to sequences showing identity

to the specified DNA or polypeptide sequence. DNA sequences that are substantially homologous can be identified in a Southern hybridization experiment under, for example, stringent conditions, as defined for that particular system.

Defining appropriate hybridization conditions is within the skill of the art. See, e.g., 5 "Current Protocols in Mol. Biol." Vol. I & II, Wiley Interscience. Ausbel *et al.* (ed.) (1992). Protein sequences that are substantially the same can be identified by proteolytic digestion, gel electrophoresis and microsequencing.

The term "functionally equivalent" intends that the amino acid sequence of the subject protein is one that will elicit a catalytic response 10 substantially equivalent to the specified PDE IV_B peptide.

A "heterologous" region of a DNA construct is an identifiable segment of DNA within or attached to another DNA molecule that is not found in association with the other molecule in nature. Thus, when the heterologous region encodes a receptor gene, the gene will usually be flanked by DNA that does not 15 flank the gene in the genome of the source animal. Another example of a heterologous coding sequence is a construct where the coding sequence itself is not found in nature (e.g., synthetic sequences having codons different from the native gene). Allelic variation or naturally occurring mutational events do not give rise to a heterologous region of DNA, as used herein.

20 A "high affinity" rolipram binding site is characterized by a K_i for rolipram of about 10nM or less, whereas a "low affinity" rolipram binding site is characterized by a K_i for rolipram of about 100nM or greater.

The term ligand as used herein means any molecule that can bind or interact 25 with the PDE IV_B enzyme. When a ligand binds to the active site of the enzyme and is catalytically acted upon, the ligand is known as a substrate. Inhibitors are ligands which may or may not bind at the active site of the enzyme.

This invention provides an isolated nucleic acid molecule encoding a human PDE IV_B. Such an enzyme is defined by the criteria discussed above for members 30 of this unique subtype. One means for isolating a human PDE IV_B coding nucleic acid is to probe a human genomic or cDNA library with a natural or artificially designed probe using art recognized procedures (See for example: "Current Protocols in Molecular Biology", Ausubel, F.M., et al. (eds.) Greene Publishing Assoc. and John Wiley Interscience, New York, 1989,1992). One particularly useful probe for this purpose is a probe incorporating all, or a hybridizable 35 fragment, of a DNA of the sequence disclosed herein as Seq. ID. No. 1. Alternatively, as describe hereinbelow, probes from PDE IV_A may also be used. The isolated nucleic acid molecules obtained hereby may be used to obtain

complementary copies of genomic DNA, cDNA or RNA from human, mammalian or other animal sources or to screen such sources for related sequences including transcriptional regulatory and control elements defined above as well as other stability, processing, translation and tissue specificity-determining regions from 5' 5 and/or 3' regions relative to the coding sequences disclosed herein. Additional coding sequences isolated by the procedures disclosed herein are considered to be substantially the same as the coding sequence given in Seq. ID. No. 1 if the additional sequence shares about 93% homology with the sequence of Seq. ID. No. 1.

10 This invention also provides for an isolated protein which is the human PDE IV_B. This enzyme is defined with reference to the amino acid sequence listed in Seq. ID. No. 2 and includes variants with a substantially homologous amino acid sequence but retaining the criteria of a PDE IV_B enzyme identified herein. The proteins of this invention are preferably made by recombinant genetic engineering 15 techniques. The isolated nucleic acids particularly the DNAs can be introduced into expression vectors by operatively linking the DNA to the necessary expression control regions (e.g. regulatory regions) required for gene expression. The vectors can be introduced into the appropriate host cells such as prokaryotic (e.g., bacterial), or eukaryotic (e.g., yeast or mammalian) cells by methods well known in the art 20 (Ausubel et al., *supra*). The coding sequences for the desired proteins having been prepared or isolated, can be cloned into any suitable vector or replicon. Numerous cloning vectors are known to those of skill in the art, and the selection of an appropriate cloning vector is a matter of choice. Examples of recombinant DNA vectors for cloning and host cells which they can transform include the bacteriophage 25 λ (*E. coli*), pBR322 (*E. coli*), pACYC177 (*E. coli*), pKT230 (gram-negative bacteria), pGV1106 (gram-negative bacteria), pLAFR1 (gram-negative bacteria), pME290 (non-*E. coli* gram-negative bacteria), pHV14 (*E. coli* and *Bacillus subtilis*), pBD9 (*Bacillus*), pIJ61 (*Streptomyces*), pUC6 (*Streptomyces*), YIp5 (*Saccharomyces*), a baculovirus insect cell system, YCp19 (*Saccharomyces*). See, 30 generally, "DNA Cloning": Vols. I & II, Glover et al. ed. IRL Press Oxford (1985) (1987) and; T. Maniatis et al. "Molecular Cloning" Cold Spring Harbor Laboratory (1982).

35 The gene can be placed under the control of a promoter, ribosome binding site (for bacterial expression) and, optionally, an operator (collectively referred to herein as "control" elements), so that the DNA sequence encoding the desired protein is transcribed into RNA in the host cell transformed by a vector containing this expression construction. The coding sequence may or may not

contain a signal peptide or leader sequence. The subunit antigens of the present invention can be expressed using, for example, the *E. coli* tac promoter or the protein A gene (spa) promoter and signal sequence. Leader sequences can be removed by the bacterial host in post-translational processing. See, e.g., U.S. Patent Nos. 4,431,739; 5 4,425,437; 4,338,397.

In addition to control sequences, it may be desirable to add regulatory sequences which allow for regulation of the expression of the protein sequences relative to the growth of the host cell. Regulatory sequences are known to those of skill in the art, and examples include those which cause the expression of a gene to be 10 turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. Other types of regulatory elements may also be present in the vector, for example, enhancer sequences.

An expression vector is constructed so that the particular coding sequence is located in the vector with the appropriate regulatory sequences, the 15 positioning and orientation of the coding sequence with respect to the control sequences being such that the coding sequence is transcribed under the "control" of the control sequences (i.e., RNA polymerase which binds to the DNA molecule at the control sequences transcribes the coding sequence). Modification of the sequences encoding the particular antigen of interest may be desirable to achieve this end. For 20 example, in some cases it may be necessary to modify the sequence so that it may be attached to the control sequences with the appropriate orientation; i.e., to maintain the reading frame. The control sequences and other regulatory sequences may be ligated to the coding sequence prior to insertion into a vector, such as the cloning vectors described above. Alternatively, the coding sequence can be cloned directly 25 into an expression vector which already contains the control sequences and an appropriate restriction site.

In some cases, it may be desirable to add sequences which cause the secretion of the polypeptide from the host organism, with subsequent cleavage of the secretory signal. It may also be desirable to produce mutants or analogs of the 30 receptors of interest. Mutants or analogs may be prepared by the deletion of a portion of the sequence encoding the protein, by insertion of a sequence, and/or by substitution of one or more nucleotides within the sequence. Techniques for modifying nucleotide sequences, such as site-directed mutagenesis, are well known to those skilled in the art. See, e.g., T. Maniatis *et al.*, *supra*; *DNA Cloning*, Vols. I and 35 II, *supra*; *Nucleic Acid Hybridization*, *supra*.

A number of prokaryotic expression vectors are known in the art. See, e.g., U.S. Patent Nos. 4,578,355; 4,440,859; 4,436,815; 4,431,740; 4,431,739;

4,428,941; 4,425,437; 4,418,149; 4,411,994; 4,366,246; 4,342,832; see also U.K. Patent Applications GB 2,121,054; GB 2,008,123; GB 2,007,675; and European Patent Application 103,395. Yeast expression vectors are also known in the art. See, e.g., U.S. Patent Nos. 4,446,235; 4,443,539; 4,430,428; see also European Patent Applications 103,409; 100,561; 96,491. pSV2neo (as described in J. Mol. Appl. Genet. 1:327-341) which uses the SV40 late promoter to drive expression in mammalian cells or pCDNA1neo, a vector derived from pCDNA1(Mol. Cell Biol. 7:4125-29) which uses the CMV promoter to drive expression. Both these latter two vectors can be employed for transient or stable(using G418 resistance) expression in mammalian cells. Insect cell expression systems, e.g., Drosophila, are also useful, see for example PCT applications US 89/05155 and US 91/06838 as well as EP application 88/304093.3.

Depending on the expression system and host selected, the proteins of the present invention are produced by growing host cells transformed by an expression vector described above under conditions whereby the protein of interest is expressed. It is preferred to employ as a host a cell type that produced little or no endogenous PDE IV so as to make the identification and recovery of the recombinant form easier. The protein is then isolated from the host cells and purified. If the expression system secretes the protein into growth media, the protein can be purified directly from the media. If the protein is not secreted, it is isolated from cell lysates or recovered from the cell membrane fraction. In certain cases where the protein is localized to the cell surface, whole cells or isolated membranes can be used as an assayable source of the desired gene product. The selection of the appropriate growth conditions and recovery methods are within the skill of the art.

An alternative method to identify proteins of the present invention is by constructing gene libraries, using the resulting clones to transform E. coli and pooling and screening individual colonies using polyclonal serum or monoclonal antibodies to the desired enzyme.

The proteins of the present invention may also be produced by chemical synthesis such as solid phase peptide synthesis, using known amino acid sequences or amino acid sequences derived from the DNA sequence of the genes of interest. Such methods are known to those skilled in the art. Chemical synthesis of peptides is not particularly preferred.

The proteins of the present invention or their fragments comprising at least one epitope can be used to produce antibodies, both polyclonal and monoclonal. If polyclonal antibodies are desired, a selected mammal, (e.g., mouse, rabbit, goat, horse, etc.) is immunized with a receptor of the present invention, or its fragment, or

a mutated receptor. Serum from the immunized animal is collected and treated according to known procedures. If serum containing polyclonal antibodies is used, the polyclonal antibodies can be purified by immunoaffinity chromatography or other known procedures.

5 Monoclonal antibodies to the proteins of the present invention, and to the fragments thereof, can also be readily produced by one skilled in the art. The general methodology for making monoclonal antibodies by using hybridoma technology is well known. Immortal antibody-producing cell lines can be created by cell fusion, and also by other techniques such as direct transformation of B 10 lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus. See, e.g., M. Schreier *et al.*, "Hybridoma Techniques" (1980); Hammerling *et al.*, "Monoclonal Antibodies and T-cell Hybridomas" (1981); Kennett *et al.*, "Monoclonal Antibodies" (1980); see also U.S. Patent Nos. 4,341,761; 4,399,121; 4,427,783; 4,444,887; 4,452,570; 4,466,917; 4,472,500; 4,491,632 and 4,493,890. Panels of monoclonal 15 antibodies produced against the antigen of interest, or fragment thereof, can be screened for various properties; i.e., for isotype, epitope, affinity, etc. Monoclonal antibodies are useful in purification, using immunoaffinity techniques, of the individual antigens which they are directed against. Alternatively, genes encoding the monoclonals of interest may be isolated from the hybridomas by PCR techniques 20 known in the art and cloned and expressed in the appropriate vectors. The antibodies of this invention, whether polyclonal or monoclonal have additional utility in that they may be employed reagents in immunoassays, RIA, ELISA, and the like.

In other embodiments cell membrane fractions comprising the enzyme, partially purified supernatants containing the enzyme or isolated enzyme free or 25 immobilized on solid supports may be used to measure binding of compounds to be tested. When recombinant cells are used for purposes of expression of the enzyme, it is preferred to use cells with little or no endogenous enzyme activity so that binding if any is due to the presence of the expressed enzyme of interest. Preferred cells include yeast cells, particularly those of Saccharomyces cerevisiae that have been engineered 30 to lack endogenous PDE activity. In a further embodiment a specific localization of PDE IV_B can be achieved. For example a fusion protein can be made by fusing the enzyme of this invention with a protein domain which directs incorporation of such a fusion into the cell wall or cell membrane of the host cell. Such a domain, referred to here as a cell surface localizing domain, is capable, itself, or in association with 35 accessory signal sequences known in the art, of directing the expression of the fusion protein and its integration into the host cell membrane or cell wall. It is most

preferable to integrate the fusion protein so that the PDE IV_B domain is displayed on the external surface of the host cell.

In the compound screening embodiment of this invention, the enzyme partially purified or in isolated, immobilized or cell bound form is contacted with a plurality of 5 candidate molecules and those candidates are selected which bind to and interact with the enzyme (e.g., enzyme inhibitors). The binding or interaction can be measured directly by using radioactively labeled candidate of interest.

Alternatively, the candidate compounds can be subjected to a competition screening assays, in which a known ligand (e.g., rolipram), preferably labeled with an 10 analytically detectable reagent, most preferably radioactivity, is introduced with the compound to be tested and the compound's capacity to inhibit or enhance the binding of the labeled ligand is measured. Compounds are screened for their increased affinity and selectivity to the enzyme class of interest. In yet another approach advantage is taken of the catalytic activity of PDE IV_B. Specifically, since PDE IV_B hydrolyzes 15 the 3'-phosphoester bond of cyclic nucleotides (e.g., cyclic AMP) to form 5'- monophosphate products, candidate molecules can be screened for their ability to inhibit the hydrolysis of cyclic nucleotides labeled with the appropriate analytically detectable reagent (e.g., radioactive, fluorometric or colorimetric agent).

In yet another embodiment human PDE IV_B functionally expressed in host 20 cells, especially yeast may be employed in a rapid, high-throughput screen to identify enzyme-selective inhibitors from sources such as natural products. Cells of Saccharomyces cerevisiae contain two genes that encode endogenous cAMP PDEs (Sass, P. et al., Proc. Nat'l. Acad. Sci. USA 83:9303-07 (1986); Wilson, R.B. et al., 25 Mol. Cell. Biol. 8:505-510 (1988) and Nikawa, J.I. et al., Mol. Cell. Biol. 7:3629-36 (1987)). PDE-deficient mutants were constructed by reverse genetic techniques (gene disruption) according to the method of Rothstein et al. (Cloning in Yeast. In: "DNA Cloning II: a practical approach", D.M. Glover ed., IRL Press, Washington D.C., pgs 45-66 (1990)) and were found to be viable, but to exhibit specific growth 30 arrest phenotypes associated with elevated cAMP content. These phenotypes include: heat shock sensitivity, sensitivity to nitrogen starvation and the inability to grow on media containing suboptimal carbon sources such as acetate. The details for the agar plate assay (i.e., media composition and conditions for assaying growth arrested phenotype) are described in Sass et al. supra; Wilson et al., supra; Nikawa et al., supra and McHale, M.M. et al., Mol. Pharm. 39:109-113 (1991). Briefly, cells 35 are grown in SC-Trp liquid medium for 2 days at 30° C, spotted onto SC-Trp agar medium containing 5mM cAMP and 150μM CuSO₄ and incubated for 2 days at 30° C. For heat shock, cells are replicated from the master plate onto two plates each

containing the same medium as describe above, one of which is preheated to 55°C for 1 hour. Cells transferred to the preheated plate are incubated at 55°C for 5 minutes and then shifted to 30°C. For monitoring growth on acetate, the master plate is replicated to a plate containing the same medium except 2% potassium acetate instead of glucose. Growth is scored after five days at 5 days at 30° C.

5 Functional expression of human PDE IV_A or PDE IV_B in genetically engineered PDE-deficient strains of *S. cerevisiae* reverses the aberrant phenotypes described above. Furthermore, under conditions for growth arrest, rolipram, as well as certain other selective mammalian PDE IV inhibitors, are cytotoxic to PDE-10 deficient mutant cells expressing the human PDE IV under growth arrest conditions. At the same time, rolipram has no killing effect on either wild-type yeast cells or on PDE-deficient cells expressing the human PDE IVs under normal growth conditions. These controls indicate that rolipram is not simply acting as an antifungal agent. Instead, it is entering the yeast cells and inhibiting the activity of the human 15 recombinant enzyme in the cells; this, in turn, results in an elevation of cAMP content and an unmasking of the concomitant growth arrest phenotype.

Such a system provides the basis for a high throughput screen for PDE IV subtype-specific inhibitors. The source of compound for screening includes pure chemicals as well as natural products (e.g., fermentation broths from soil 20 microorganisms, extracts from plants, animals and marine microorganisms). In such a screen compounds are identified by the ability to kill cells incubated under the prescribed conditions for growth arrest (where cell viability depends on the functional expression (biological activity) of the human recombinant PDE IV) but at the same time, not affect wild-type cells. Although yeast cells may possess certain barriers 25 (i.e., cell wall) that may make them less sensitive than mammalian cells to certain small molecules, such shortcomings are readily overcome by increasing the permeability of the yeast cell by for example, mutating genes that effect the synthesis of cell membrane components (e.g., ergosterol) See for example, Gaber, R.F., et al., *Mol. Cell. Biol.* 9:3447-3456 (1989).

30 This system also offers an excellent method for rapidly assaying genetically engineered site specific mutants of human PDE IV_B for functional catalytic activity in cells. Furthermore, this system allows for the direct selection of rolipram-resistant and catalytically active mutants of PDE IV which when characterized in terms of DNA sequence may reveal amino acid residues involved in compound binding.

35 New compounds found to specifically inhibit the recombinant enzyme in vitro (see above) are then compared to rolipram or other reference compounds with respect to their capacity to unmask the inherent growth arrest phenotypes present in

the yeast screening strains under appropriate culture conditions. In addition PDE IV inhibitors identified in natural products can be chemically purified and assayed for the ability to inhibit the recombinant enzyme(s) *in vitro*.

In yet another aspect of this invention, the discovery of the heretofore 5 unknown human PDE IV_B subtype provides a new method for rapidly screening subtype-specific inhibitors. Accordingly, the PDE IV A and B subtypes are expressed in separate PDE-deficient yeast strains and candidate compounds are screened for their ability to inhibit one but not both the enzyme subtypes. Thus 10 compounds may be identified that inhibit the monocyte A form but not the brain B form of PDE IV.

This invention also contemplate pharmaceutical compositions comprising 15 compounds when identified by the above methods and a pharmaceutically acceptable carrier. Pharmaceutical compositions of proteineous drugs of this invention are particularly useful for parenteral administration, i.e., subcutaneously, intramuscularly or intravenously. The compositions for parenteral administration will commonly 20 comprise a solution of the compounds of the invention or a cocktail thereof dissolved in an acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers may be employed, e.g., water, buffered water, 0.4% saline, 0.3% glycine, and the like. These solutions are sterile and generally free of particulate matter. These 25 solutions may be sterilized by conventional, well known sterilization techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, etc. The concentration of the compound of the invention in such pharmaceutical formulation can vary widely, i.e., from less than about 0.5%, usually 30 at or at least about 1% to as much as 15 or 20% by weight and will be selected primarily based on fluid volumes, viscosities, etc., according to the particular mode of 35 administration selected.

Thus, a pharmaceutical composition of the invention for intramuscular injection could be prepared to contain 1 ml sterile buffered water, and 50 mg of a 30 compound of the invention. Similarly, a pharmaceutical composition of the invention for intravenous infusion could be made up to contain 250 ml of sterile Ringer's solution, and 150 mg of a compound of the invention. Actual methods for preparing parenterally administrable compositions are well known or will be apparent to those skilled in the art and are described in more detail in, for example, Remington's 35 Pharmaceutical Science, 15th ed., Mack Publishing Company, Easton, Pennsylvania.

The compounds described herein can be lyophilized for storage and reconstituted in a suitable carrier prior to use. This technique has been shown to be

effective with conventional proteins and art-known lyophilization and reconstitution techniques can be employed.

In situations where the identified compound is non-proteinaceous, it may be administered alone or in combination with pharmaceutically acceptable carriers. The proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration and standard pharmaceutical practice. For example, they may be administered orally in the form of tablets or capsules containing such excipients as starch, milk sugar, certain types of clay and so forth. They may be administered sublingually in the form of troches or lozenges in which the active ingredient is mixed with sugar and corn syrups, flavoring agents and dyes; and then dehydrated sufficiently to make it suitable for pressing into a solid form. They may be administered orally in the form of solutions which may be injected parenterally, that is, intramuscularly, intravenously or subcutaneously. For parenteral administration they may be used in the form of a sterile solution containing other solutes, for example, enough saline or glucose to make the solution isotonic.

The physician will determine the dosage of the present therapeutic agents which will be most suitable and it will vary with the form of administration and the particular compound chosen, and furthermore, it will vary with the particular patient under patient under treatment. He will generally wish to initiate treatment with small dosages substantially less than the optimum dose of the compound and increase the dosage by small increments until the optimum effect under the circumstances is reached. It will generally be found that when the composition is administered orally, larger quantities of the active agent will be required to produce the same effect as a smaller quantity given parenterally. The compounds are useful in the same manner as other PDE IV_B- effecting agents and the dosage level is of the same order of magnitude as is generally employed with these other therapeutic agents. The therapeutic dosage will generally be from 1 to 10 milligrams per day and higher although it may be administered in several different dosage units. Tablets containing from 0.5 to 10 mg. of active agent are particularly useful.

Depending on the patient condition, the pharmaceutical composition of the invention can be administered for prophylactic and/or therapeutic treatments. In therapeutic application, compositions are administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the disease and its complications. In prophylactic applications, compositions containing the present compounds or a cocktail thereof are administered to a patient not already in a disease state to enhance the patient's resistance.

Single or multiple administrations of the pharmaceutical compositions can be carried out with dose levels and pattern being selected by the treating physician. In any event, the pharmaceutical composition of the invention should provide a quantity of the compounds of the invention sufficient to effectively treat the patient.

5 The nucleic acid embodiment of this invention is particularly useful in providing probes capable of specific hybridization with human PDE IV_B sequences. Probing technology is well known in the art and it is appreciated that the size of the probes can vary widely but it is preferred that the probe be at least 15 nucleotides in length. It is also appreciated that such probes can be and are preferably labeled with
10 an analytically detectable reagent to facilitate identification of the probe. Useful reagents include but are not limited to radioactivity, fluorescent dyes or enzymes capable of catalyzing the formation of a detectable product. This invention contemplates, for example using PDE IV_B encoding probes in the diagnostic evaluation of disease states characterized by an abnormal, i.e., increased or decreased
15 level of PDE IV_B gene expression. Alternatively, the probes can be used to identify individuals carrying chromosomal or molecular mutations in the gene encoding the enzyme. Depending on the conditions employed by the ordinary skilled artisan, the probes can be used to identify and recover additional examples of the PDE IV_B enzyme from other cell types and individuals. As a general rule the more stringent
20 the hybridization conditions the more closely related genes will be that are recovered.

Also within the scope of this invention are antisense oligonucleotides predicated upon the sequences disclosed herein for the PDE IV_B enzyme. Synthetic oligonucleotides or related antisense chemical structural analogs are designed to recognize and specifically bind to a target nucleic acid encoding the receptor gene
25 and inhibit gene expression, e.g., the translation of the gene when the target nucleic acid is mRNA. Although not wishing to be bound to a particular theory for the mechanism of action of antisense drugs, it is believed that such drugs can act by one or more of the following mechanisms: by binding to mRNA and inducing degradation by endogenous nucleases such as RNase I or by inhibiting the translation of mRNA
30 by binding to regulatory factors or ribosomal components necessary for productive protein synthesis. Additionally the antisense sequences can be used as components of a complex macromolecular arrays in which the sequences are combined with ribozyme sequences or reactive chemical groups and are used to specifically target mRNAs of interest and degrade or chemically modify said mRNAs. The general field
35 of antisense technology is illustrated by the following disclosures which are incorporated herein by reference for purposes of background (Cohen, J.S., Trends in

Pharm. Sci. 10:435(1989) and Weintraub, H.M. Scientific American Jan.(1990) at page 40).

This invention also contemplates antibodies, monoclonal or polyclonal directed to epitopes corresponding to amino acid sequences disclosed herein from the 5 PDE IV_B enzyme. Particularly important regions of the enzyme for immunological purposes are those catalytic and allosteric domains of the enzyme. Antibodies or fragments thereof directed to these regions are particularly useful in diagnostic and therapeutic applications because of there effect upon enzyme-ligand interaction. Methods for the production of polyclonal and monoclonal antibodies are well known, 10 see for example Chap. 11 of Ausubel *et al.* (*supra*).

This invention also provides pharmaceutical compositions comprising an effective amount of antibody or antigen binding fragments thereof directed against the PDE IV_B enzyme to block binding of naturally occurring ligands to that enzyme in order to treat or ameliorate disease states associated with inappropriate enzyme 15 activation. In its diagnostic embodiment the PDE IV_B enzyme can be detected by contacting it with antibodies of this invention and measuring the antibody/enzyme complex. When the antibody is labeled with an analytically detectable reagent such a radioactivity, fluorescence, or an enzyme, the antibody can be use to detect the presence or absence of the enzyme and/or its quantitative level.

20 As disclosed herein below, screening a human frontal cortex library revealed the existence of a unique cDNA that encodes a protein with 76% amino acid sequence identity to hPDE IV_A. Expression of this cDNA in PDE-deficient yeast cells indicates that the gene product possesses characteristics consistent with those of the PDE IV enzyme family. Specifically, the recombinant enzyme, designated 25 hPDE IV_B, has a cAMP K_m = 4μM and exhibits very poor activity with cGMP as a substrate. Moreover, the activity of this enzyme is inhibited by rolipram (K_i = 0.085 μM) and other PDE IV-selective inhibitors, but not by compounds that selectively inhibit other PDE isozymes. Similar to the results obtained with hPDE IV_A, rolipram does not inhibit hPDE IV_B activity in a purely competitive fashion. 30 While not wishing to be bound by any particular explanation, this could reflect a kinetically complex mechanism of inhibition by rolipram (e.g., allosteric interaction) or could indicate that the recombinant hPDE IV_B exists in two distinct, catalytically active, non-interconvertable forms, both of which can be inhibited competitively by rolipram but with significantly different K_is. Based upon the 35 limited evaluation of hPDE IV_B carried out thus far, it appears that the kinetic properties of this subtype are similar to hPDE IV_A.

As observed with hPDE IV_A, hPDE IV_B catalytic activity and high affinity rolipram binding are coexpressed. Thus, high affinity rolipram binding is a property of both hPDE IV_A and hPDE IV_B. Interestingly, at least two classes of kinetically distinct high affinity rolipram-binding sites exist on hPDE IV_B ($K_{dS} = 0.4$ and 6 nM), whereas only one class ($K_d = 2$ nM) is present on hPDE IV_A.

Valuable information regarding enzyme structure and function can be obtained from comparisons of the predicted primary amino acid sequences of different PDEs. All of the well-studied mammalian PDEs exhibit a common structure consisting of a highly conserved 270-300 amino acid sequence within the central core of the molecule corresponding to the catalytic domain, flanked by variable N-terminal and C-terminal extensions. Based on a considerable amount of biochemical data, the conserved region contains the information for catalytic activity, whereas the nonconserved regions may dictate subtype-specificity in terms of regulation of enzymatic activity, cellular distribution or subcellular localization. Alignment of the primary amino acid sequence of hPDE IV_B with that of one of the rat brain enzymes (rPDE IV_B in Fig. 2) shows that they are nearly identical (from residues 38 to 564); this conservation of sequence includes the C-terminal end of each molecule. In contrast, comparison of the hPDE IV_A and hPDE IV_B subtypes reveals striking sequence divergence, especially at the N-terminal and C-terminal ends. This suggests that there is a greater degree of sequence conservation between the "same" isozyme subtype from different species than among "different" subtypes from the same species.

Although significant structural similarity in the conserved regions was observed between of hPDE IV_A (which is known to be expressed in human monocytes), and one of the enzymes cloned from a rat brain cDNA library (rPDE IV_A in Fig. 2), it is impossible to draw a conclusion regarding the functional relationship between these two subtypes considering the extensive sequence divergence present at their N-terminal and C-terminal ends. The prominent characteristic that separates these two subtypes from the others, however, is the long C-terminal domain. It is quite possible the two subtypes are functionally equivalent, and that the rat brain enzyme is not really brain-specific. That is, the mRNA template for the rat brain cDNA could actually have come from contaminating blood monocytes. Unfortunately, the analysis of the tissue-distribution of the rat PDE IV transcripts, which showed expression in all tissues examined, used full-length cDNAs as probes and therefore did not differentiate the expression of various subtypes (Swinnen, J.V. et al., *Proc. Natl. Acad. Sci. USA* 86:5325-5329 (1989)).

Using a DNA probe consisting of nonconserved sequences, the human tissue distribution of hPDE IV_B mRNA was analyzed herein and found to exhibit a restricted pattern of expression. An ~4-kb message was easily detected in brain, as well as in three other tissues, but not in placenta, liver, kidney and pancreas. In 5 brain, we observed an additional ~5-kb mRNA species which may represent unprocessed mRNA. Alternatively, the identification of two hPDE IV_B-related mRNAs in brain tissue may correspond to differentially spliced transcripts expressed from the same gene, or instead, may indicate the presence of another as yet unidentified gene.

10 More important is the differential response of hPDE IV_A and hPDE IV_B to inhibitors. Predicated upon such a response, subtype specific drug screening can be developed. In one embodiment of this invention a screening protocol may be conducted as outline hereinabove.

15

Example 1

This example provides the details of the cloning, expressing and characterization of the PDE IV_B of this invention.

5

Experimental Procedures

Isolation of cDNA--A commercially prepared human frontal cortex cDNA library constructed in λ ZAP (Stratagene; average insert size - 1.5 kb) was screened with a 32 P-labeled (random-primed; Pharmacia) 1.8-kb SmaI fragment of the 10 human monocyte cDNA clone hm-PDE1 (formerly hPDE-1) which encodes a PDE IV. Hybridizations were carried out at 65°C in 6X SCP (0.6 M NaCl, 0.81 M Na₂HPO₄, 6 mM EDTA, pH 6.2), 10% dextran sulfate, 5X Denhardt's (0.01% ficoll, 0.01% polyvinylpyrrolidone, 0.01% bovine serum albumin), 0.1% SDS and 100 mg/ml salmon sperm DNA. Filters were washed in 2X SCP, 0.1% SDS at 65° 15 C. and autoradiographed. A number of clones were isolated and partially characterized by restriction mapping. DNA sequencing of one 2.7-kb clone (hb-PDE1a) by the method of Sanger, F. *et al.* (*Proc. Natl. Acad. Sci. USA* 74:5463-67 (1977)) revealed that it contained a truncated ORF, predicting a protein with homology to only the 3' half of PDE protein encoded by hm-PDE1. A 0.69-kb 20 NdeI-SphI fragment, containing the majority of the ORF of clone hb-PDE1a was then used to screen a custom cDNA library prepared at Stratagene from human frontal cortex tissue (also in λ ZAP). This library was prepared using methods to insure large insert sizes. Briefly, the RNA was denatured in the presence of methyl mercury and converted to cDNA using 80% oligo dT and 20% random priming. 25 The cDNA was then size-selected for inserts of 1.5-kb and greater by agarose gel electrophoresis. Labeling, hybridization and washing conditions were identical to those stated above. This screen yielded 11 clones which were analyzed by restriction mapping. The DNA sequence of the largest clone, hb-PDE1, was determined and found to overlap the sequence of hb-PDE1a by 1.35 kb, and extend 30 1.28 kb further upstream (5'); the total size of hb-PDE1 is 2.63 kb. Thus, the composite of hb-PDE1a and hb-PDE1 represent a cDNA containing both 5' and 3' UTRs. hb-PDE1 alone encodes a full-length PDE IV-related protein (called hPDE IV_B) as judged by an alignment of its primary amino acid sequence with that of other PDE IV subtypes (see Figure 2). 35 *Northern Analysis* -- An "hb-PDE1-specific" DNA probe was generated by PCR (see: Mullis, K.B. and F.A. Falloona, *Meth of Enz.* 155:335-50 (1987)) using the

following oligonucleotide primers: 5'-
GGGGCTCGAGGAGGGACACACGTATTT-
CAGCAGCACAAAG-3' (Seq. ID No:3) and 3'-
CTCACTTGAGTGACTGATTATTGAAGT-
5 AAAGAGCTCGGGG-5' (Seq. ID No:4) This fragment was subcloned into pGEM7
(Promega) using the unique XbaI sites (underlined). The XbaI fragment was gel
purified, ³²P-labeled (random-primed; Pharmacia), and hybridized to a Northern
blot containing poly (A)⁺ RNA extracted from multiple human tissues (Clonetech);
hybridization conditions were: 42°C in 5X SSPE (0.75M NaCl, 0.2 M
10 NaH₂PO₄·H₂O, 5mM Na₂EDTA, pH7.4), 10X Denhardt's, 100 mg/ml salmon
sperm DNA, 50% formamide and 2% SDS. The blot was washed in 0.1X SSC (15
mM NaCl, 1.5 mM sodium citrate, pH7.0), 0.1% SDS at 50°C and
autoradiographed. The same blot was stripped with boiling water and reprobed with
a 2-kb human β-actin-encoding cDNA (see: Cleveland, D.W. et al. *Cell* 20:95-105
15 (1980)). Labeling, hybridization and washing conditions were the same as above.
Expression of hPDE IV_B in *Saccharomyces cerevisiae*-- The hb-PDE1 cDNA
was engineered for expression in yeast as follows: the 2.08-kb XbaI (5' polylinker)
- NcoI fragment of pBluescript/hb-PDE1 was subcloned into the unique XbaI and
NcoI polylinker sites of the yeast expression plasmid p138NB (McHale, M.M. et al.
20 *Mol. Pharmacol.* 39:109-113 (1991)). The 5' UTR of hb-PDE1 was then deleted by
removing the 1.1-kb XbaI-PvuII fragment and replacing it with a 0.79-kb XbaI-
PvuII hb-PDE1 fragment generated by PCR in which a XbaI site was engineered
just upstream of the initiating methionine codon. The oligonucleotide primers used
for PCR were: 5'-
25 GGGGGCTCGAGATGAAGGAGCACGGGGCACCTTCAGTAGC-3' (Seq. ID
No:5) and 3'-GACGGTAAAACGTCGACGGTAGGTACTGC-5' (Seq. ID No:6).
The PCR-generated portion of this plasmid (p138NB/hb-PDE1) was sequenced and
found to contain one base pair change that did not affect the amino acid sequence.
p138NB/hb-PDE1 contains the TRP1 selectable marker and partial 2μ
30 sequences for maintenance at high copy number, with hb-PDE1 expression driven
by the copper inducible CUP1 gene promoter. The plasmid was introduced into the
PDE-deficient *S. cerevisiae* strain GL62 (isogenic to strain GL61; described in
McHale et al. (*supra*) (1991)) using the lithium acetate method (Ito, H., et al. *J.*
Bacteriol. 153:163-168 (1983)). Trp⁺ prototroph were isolated and grown
35 aerobically at 30°C to an A₅₄₀ = 1.0 in synthetic complete medium lacking
tryptophan. PDE expression was induced by the addition of 150 μM CuSO₄. Cells

were harvested at 6 hr and 100,000 x g supernatants were prepared as previously described by McHale et al. (*supra*).

PDE Assays and Inhibitor Studies -- PDE activity was determined in 100,000 x g supernatant fractions of yeast cell lysates. Briefly, the reaction was initiated by the addition of an aliquot of the yeast supernatant fraction to 0.1 ml (final volume) of a reaction mixture containing (final concentrations) 50 mM Tris-HCl (pH 7.5), 5 mM MgCl₂, 1 μ M [³H] cAMP (2000 dpm/pmol) and 0.05% BSA. To determine recovery, 50 μ M 5'-[¹⁴C] AMP (400 dpm/nmol) was added to each assay tube after the reaction was terminated. For studies in which the IC₅₀s of various inhibitors were determined, compounds were present in the reaction mixture at concentrations that varied over three orders of magnitude. Reactions were conducted at 30°C for 30 min. The reactions were terminated, 5'-adenosine monophosphate was isolated, and PDE activity was determined as previously described (Torphy, T.J. and L.B. Cieslinski, *Mol. Pharmacol.* 37:206-214 (1990)). All assays were conducted in the linear range of reaction within which no greater than 10% of the initial substrate is hydrolyzed. cGMP hydrolysis was also assayed as described by Torphy, T.J. and Cieslinski (*supra*). Protein concentrations were determined as previously described (Lowry, O.H. et al. *J. Biol. Chem.* 193:265-75 (1951)).

Rolipram Binding Assay -- [³H] R-Rolipram binding was assessed by modification of the method of Schneider and co-workers (*Eur. J. Pharmacol.* 127:105-115 (1986)). For competition binding experiments, the reaction was conducted at 30°C in 0.5 ml of a standard reaction mixture containing (final concentrations): 50 mM Tris-HCl (pH7.5), 5 mM MgCl₂, 50 μ M 5'-AMP, 2 nM [³H] R-rolipram (5.7×10^4 dpm/pmol) and 0.05% BSA. For saturation binding experiments, the concentration of [³H] R-rolipram was varied from 0.02-24 nM. Nonspecific binding was defined in the presence of 1 μ M unlabeled rolipram and was consistently less than 5% of total binding. The reaction was stopped after 1 h by the addition of 1 ml ice-cold reaction buffer (without [³H] R-rolipram) and rapid vacuum filtration (Brandel Cell Harvester) through Whatman GF/B filters that had been soaked in 0.3% polyethylenimine. The filters were washed with an additional 5 ml of cold buffer, dried and counted via liquid scintillation spectrometry.

Determination of Kinetic and Binding Parameters--For determination of V_{max}, K_m, and K_i, the concentration of cAMP or cGMP was varied while the amount of ³H-labeled cyclic nucleotide per assay was kept constant. Appropriate corrections were made for the changes in specific activity of the substrate. Kinetics were analyzed with a KINPAC computer program described by W.W. Cleland (*Meth. of Enzymol.* 63:103-38 (1979)), using a nonlinear least-squares regression

analysis. Analysis of [³H] R-rolipram binding experiments, including determination of multiple K_d and V_{max} values, was carried out using the Acufit computer program (Beckman Instruments, Fullerton, CA). Statistical comparisons between one-site and two-site fits were conducted via F test.

5 Inhibitors and radioligand--R- and (S)-rolipram were synthesized by Dr. Sigfried Christensen and colleagues (SmithKline Beecham Pharmaceuticals, King of Prussia, PA); [³H] R-rolipram (5.7×10^4 dpm/pmol) was prepared by Dr. Richard Heys and colleagues (SmithKline Beecham Pharmaceuticals, King of Prussia, PA); denbufylline was obtained from SmithKline Beecham Pharmaceuticals (Epsom, 10 United Kingdom); Ro 20-1724 was purchased from BioMol (Plymouth Meeting, PA); zaprinast and siguazodan (SK&F 94836) were synthesized by Dr. William Coates and colleagues (SmithKline Beecham Pharmaceuticals, Welwyn, United Kingdom).

15 RESULTS

Cloning and Nucleotide Sequence of a Human Brain PDE IV cDNA--A DNA fragment from the conserved region of a human monocyte cDNA shown to encode a low- K_m cAMP-specific PDE was used to probe a human frontal cortex cDNA library. Numerous clones were obtained, characterized by restriction mapping, and 20 the DNA sequence of one 2.7-kb clone was determined. This clone (hb-PDE1a) contained sequence information which was homologous to a large 3' portion of the hPDE IV_A cDNA. hb-PDE1a was then used to probe a second cDNA library which was custom synthesized from human frontal cortex. Again, numerous clones were obtained, and based on restriction analysis we determined the DNA sequence of one 25 clone containing the longest 5' extension. Fig. 1 shows the composite nucleotide sequence of these two cDNAs. hb-PDE1 extends from positions -283 to 2363, whereas hb-PDE1a extends from positions 1008 to 3609. The sequence contains an ORF of 1692 bp in length, which predicts a 564 amino acid protein with a calculated molecular mass of 64,202 (minus the N-terminal methionine). The ORF is flanked 30 by 5' and 3' untranslated sequences of 283 and 1907 bp, respectively. The 3' UTR contains a putative polyadenylation signal (5'-AATAAA-3') at position 3572, followed by a poly (A) tract.

Analysis of the Predicted hb-PDE1 Protein Sequence--Fig. 2 shows an alignment of the hPDE IV_B primary amino acid sequence with the sequences of 35 three other cloned mammalian PDE IVs, one from human monocytes (hPDE IV_A), and two from rat brain (rPDE IV_A; rPDE IV_B). Recombinant forms of all of these other enzymes have been found to exhibit the biochemical properties indicative of a

type IV PDE. There is striking homology between the hPDE IV_B protein and all of the other PDE IVs, especially within the central core of the molecule which has been proposed to contain the catalytic domain. Interestingly, the sequence of hPDE IV_B is significantly more homologous to the sequence of one of the rat brain 5 proteins (rPDE IV_B; 92% identity over 562 amino acids; 98% identity over 526 amino acids starting at residue 38 of hPDE IV_B) than to the PDE IV from human monocytes (hPDE IV_A; 76% identity over 538 amino acids) (Fig. 2). In fact, the protein sequences of hPDE IV_B and rPDE IV_B precisely align at their C-terminal ends. The relationship between these two proteins is made even more apparent by 10 the perfect alignment of sequence gaps inserted to accurately compare all four proteins (Fig. 2). It is also quite apparent that, whereas hPDE IV_B and rPDE IV_B are highly homologous to one another, the sequence of the hPDE IV_A protein is very similar to that of the other rat brain protein, rPDE IV_A (83% identity over 504 amino acids). Both hPDE IV_A and rPDE IV_A contain an insertion near the N- 15 terminal end (adjacent to residue 131 of hPDE IV_B) and a long C-terminal extensions not found on the other two proteins. Fig. 2 also shows that many of the differences between the hPDE IV_B and both the hPDE IV_A and rPDE IV_A involve residues that are conserved among the latter two proteins. Thus, there is a lesser degree of protein sequence conservation between the two human PDE IVs than 20 between two PDE IVs derived from the brain tissues from different species.

Expression of hPDE IV_B in Yeast and Evaluation of its Catalytic Activity--In order to biochemically characterize the recombinant hPDE IV_B enzyme, the hb-PDE1 cDNA was engineered for overexpression in the yeast *S. cerevisiae*. This was done using a genetically-engineered PDE-deficient strain of yeast which contained 25 genomic disruptions of the two genes encoding endogenous cAMP-specific PDEs.

Soluble fractions of yeast cells containing an expression plasmid for hPDE IV_B (p138NB/hb-PDE1) accumulated an appreciable amount of cAMP hydrolyzing activity following induction (2.0 nmol/min per mg of protein in the presence of 1 μ M [3 H]cAMP), compared to a negligible amount of activity seen in samples from 30 cells containing plasmid lacking the cDNA insert (p138NB). The hPDE IV activity expressed in yeast exhibited standard Michaelis-Menton behavior with respect to catalytic activity and a high affinity for cAMP, with a K_m of 4.3 μ M and a $V_{max}=11.3$ nmol/mg protein/min (Fig. 3A). Furthermore, R-rolipram potently inhibited catalytic activity ($K_i=0.085$ μ M), although the inhibition observed did not 35 appear to be strictly competitive (Fig. 3B). The recombinant enzyme was also inhibited by two other PDE IV inhibitors, Ro 20-1724 ($IC_{50}=2.2$ μ M) and denbufylline ($IC_{50}=0.5$ μ M), but not by siquazodan or zaprinast ($IC_{50}>30$ μ M),

inhibitors of PDE III and PDE V, respectively. No detectable hydrolysis of cGMP was noted, even at substrate concentrations as great as 10 mM.

[³H] R-rolipram Binding--A typical Scatchard analysis of saturation binding experiments with [³H] R-rolipram is shown in Fig. 4. The Scatchard plots were consistently curvilinear and best fitted a two-site model rather than a one-site model (F < 0.01). Assuming that the curvilinear Scatchard plots reflected two distinct binding sites rather than a negatively cooperative interaction, K_ds of 0.4 nM and 6 nM were calculated with the higher affinity sites representing approximately one-third of the total sites.

10 A comparison of the kinetic behavior and [³H] rolipram-binding characteristics of hPDE IV_A and hPDE IV_B is shown in Table 1. The kinetic characteristics of these subtypes are virtually identical with respect to their catalytic activity against cAMP and cGMP, as well as their sensitivity to R-rolipram. However, unlike hPDE IV_B, which appears to contain more than one high affinity 15 rolipram-binding site (Fig. 4), hPDE IV_A possesses only a single class of non-interacting high affinity binding sites.

TABLE I
Comparison of the kinetic behavior and [³H] R-rolipram binding characteristics
20 of hPDE IV_A and hPDE IV_B

Subtype	K _m		R-Rolipram K _i	[³ H] R-Rolipram K _d
	cAMP	cGMP		
hPDE IV _A ^a	3.1	>100	60	1
hPDE IV _B	4.3	>10,000	85	0.4, 6

^aData from Torphy, T.J. et al., *J. Biol. Chem.* 267:1798-1804 (1992).

mRNA Tissue Distribution--mRNA transcripts corresponding to hb-PDE1
25 were detected in only half of the human tissues surveyed (Fig. 5A). Northern blot analysis of poly (A)⁺ RNA derived from various human tissues revealed the presence of an ~4-kb mRNA in brain, heart, lung and skeletal muscle, with no

mRNA detected in placenta, liver, kidney and pancreas. An additional ~5-kb mRNA was detected in brain, present in approximately equal abundance relative to the ~4-kb mRNA (Fig. 5A). For these studies, a probe which consisted of an hb-PDE1 fragment representing a nonconserved portion of the coding region plus a portion of the 3' UTR (underlined sequence in Fig. 1) was used. The blot was stripped and reprobed with a 2-kb human β -actin cDNA as a control for the presence of RNA in each lane. Fig. 5B show that the amount of poly (A)⁺ RNA loaded from each tissue was roughly equivalent, with the exception of lung which was apparently overloaded; the lower ~1.8-kb β -actin band observed in heart and skeletal muscle represents a second muscle-specific form of the protein.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Livi, George P.
McLaughlin, Megan M.
Torphy, Theodore J.

(ii) TITLE OF INVENTION: Human Brain Phosphodiesterase

(iii) NUMBER OF SEQUENCES: 6

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: SmithKline Beecham Corporation
(B) STREET: Corporate Patents/ P.O.Box 1539
(C) CITY: King of Prussia
(D) STATE: PA
(E) COUNTRY: USA
(F) ZIP: 19406-0939

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: US
(B) FILING DATE:
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Jervis, Herbert H.
(B) REGISTRATION NUMBER: 31,171
(C) REFERENCE/DOCKET NUMBER: P50200

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (215) 270-5019
(B) TELEFAX: (215) 270-5090

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 3890 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens
(F) TISSUE TYPE: Brain

(ix) FEATURE:

(A) NAME/KEY: CDS
(B) LOCATION: 282..1973

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GGCACGAGCC TAAAGAACCT CGGGATGACT AAGGCAGAGA GAGTCTGAGA AAACCTTTG	60
GTCCTCTGC CTTTAGTTT AGGACACATT TATGCAGATG AGCTTATAAG AGACGCTTCC	120
CTCCGCCTTC TTCCCTCAGAG GAAGTTCTT GGTAGATCAG GCACACCTCA TCCAGGCGGG	180
GGGTTGGGGG GAAACTTGGC ACCAGCCATC CCAGGCAGAG CACCACTGTG ATTTGTTCTC	240
CTGGTGGAGA GAGCTGGAAG GAAGGAGCCA GCGTGCAAAT A ATG AAG GAG CAC Met Lys Glu His	293
1	
GGG GGC ACC TTC AGT AGC ACC GGA ATC AGC GGT GGT AGC GGT GAC TCT	341
Gly Gly Thr Phe Ser Ser Thr Gly Ile Ser Gly Gly Ser Gly Asp Ser	
5 10 15 20	
GCT ATG GAC AGC CTG CAG CCG CTC CAG CCT AAC TAC ATG CCT GTG TGT	389
Ala Met Asp Ser Leu Gln Pro Leu Gln Pro Asn Tyr Met Pro Val Cys	
25 30 35	
TTG TTT GCA GAA GAA TCT TAT CAA AAA TTA GCA ATG GAA ACG CTG GAG	437
Leu Phe Ala Glu Glu Ser Tyr Gln Lys Leu Ala Met Glu Thr Leu Glu	
40 45 50	
GAA TTA GAC TGG TGT TTA GAC CAG CTA GAG ACC ATA CAG ACC TAC CGG	485
Glu Leu Asp Trp Cys Leu Asp Gln Leu Glu Thr Ile Gln Thr Tyr Arg	
55 60 65	
TCT GTC AGT GAG ATG GCT TCT AAC AAG TTC AAA AGA ATG CTG AAC CGG	533
Ser Val Ser Glu Met Ala Ser Asn Lys Phe Lys Arg Met Leu Asn Arg	
70 75 80	
GAG CTG ACA CAC CTC TCA GAG ATG AGC CGA TCA GGG AAC CAG GTG TCT	581
Glu Leu Thr His Leu Ser Glu Met Ser Arg Ser Gly Asn Gln Val Ser	
85 90 95 100	
GAA TAC ATT TCA AAT ACT TTC TTA GAC AAG CAG AAT GAT GTG GAG ATC	629
Glu Tyr Ile Ser Asn Thr Phe Leu Asp Lys Gln Asn Asp Val Glu Ile	
105 110 115	
CCA TCT CCT ACC CAG AAA GAC AGG GAG AAA AAG AAA AAG CAG CAG CTC	677
Pro Ser Pro Thr Gln Lys Asp Arg Glu Lys Lys Lys Gln Gln Leu	
120 125 130	
ATG ACC CAG ATA AGT GGA GTG AAG AAA TTA ATG CAT AGT TCA AGC CTA	725
Met Thr Gln Ile Ser Gly Val Lys Lys Leu Met His Ser Ser Ser Leu	
135 140 145	
AAC AAT ACA AGC ATC TCA CGC TTT GGA GTC AAC ACT GAA AAT GAA GAT	773
Asn Asn Thr Ser Ile Ser Arg Phe Gly Val Asn Thr Glu Asn Glu Asp	
150 155 160	
CAC CTG GCC AAG GAG CTG GAA GAC CTG AAC AAA TGG GGT CTT AAC ATC	821
His Leu Ala Lys Glu Leu Glu Asp Leu Asn Lys Trp Gly Leu Asn Ile	
165 170 175 180	
TTT AAT GTG GCT GGA TAT TCT CAC AAT AGA CCC CTA ACA TGC ATC ATG	869
Phe Asn Val Ala Gly Tyr Ser His Asn Arg Pro Leu Thr Cys Ile Met	
185 190 195	
TAT GCT ATA TTC CAG GAA AGA GAC CTC CTA AAG ACA TTC AGA ATC TCA	917
Tyr Ala Ile Phe Gln Glu Arg Asp Leu Leu Lys Thr Phe Arg Ile Ser	
200 205 210	
TCT GAC ACA TTT ATA ACC TAC ATG ATG ACT TTA GAA GAC CAT TAC CAT	965

Ser Asp Thr Phe Ile Thr Tyr Met Met Thr Leu Glu Asp His Tyr His			
215	220	225	
TCT GAC GTG GCA TAT CAC AAC AGC CTG CAC GCT GCT GAT GTA GCC CAG			1013
Ser Asp Val Ala Tyr His Asn Ser Leu His Ala Ala Asp Val Ala Gln			
230	235	240	
TCG ACC CAT GTT CTC CTT TCT ACA CCA GCA TTA GAC GCT GTC TTC ACA			1061
Ser Thr His Val Leu Leu Ser Thr Pro Ala Leu Asp Ala Val Phe Thr			
245	250	255	260
GAT TTG GAG ATC CTG GCT ATT TTT GCA GCT GCC ATC CAT GAC GTT			1109
Asp Leu Glu Ile Leu Ala Ala Ile Phe Ala Ala Ala Ile His Asp Val			
265	270	275	
GAT CAT CCT GGA GTC TCC AAT CAG TTT CTC ATC AAC ACA AAT TCA GAA			1157
Asp His Pro Gly Val Ser Asn Gln Phe Leu Ile Asn Thr Asn Ser Glu			
280	285	290	
CTT GCT TTG ATG TAT AAT GAT GAA TCT GTG TTG GAA AAT CAT CAC CTT			1205
Leu Ala Leu Met Tyr Asn Asp Glu Ser Val Leu Glu Asn His His Leu			
295	300	305	
GCT GTG GGT TTC AAA CTG CTG CAA GAA GAA CAC TGT GAC ATC TTC ATG			1253
Ala Val Gly Phe Lys Leu Leu Gln Glu Glu His Cys Asp Ile Phe Met			
310	315	320	
AAT CTC ACC AAG AAG CAG CGT CAG ACA CTC AGG AAG ATG GTT ATT GAC			1301
Asn Leu Thr Lys Lys Gln Arg Gln Thr Leu Arg Lys Met Val Ile Asp			
325	330	335	340
ATG GTG TTA GCA ACT GAT ATG TCT AAA CAT ATG AGC CTG CTG GCA GAC			1349
Met Val Leu Ala Thr Asp Met Ser Lys His Met Ser Leu Leu Ala Asp			
345	350	355	
CTG AAG ACA ATG GTA GAA ACG AAG AAA GTT ACA AGT TCA GGC GTT CTT			1397
Leu Lys Thr Met Val Glu Thr Lys Lys Val Thr Ser Ser Gly Val Leu			
360	365	370	
CTC CTA GAC AAC TAT ACC GAT CGC ATT CAG GTC CTT CGC AAC ATG GTA			1445
Leu Leu Asp Asn Tyr Thr Asp Arg Ile Gln Val Leu Arg Asn Met Val			
375	380	385	
CAC TGT GCA GAC CTG AGC AAC CCC ACC AAG TCC TTG GAA TTG TAT CGG			1493
His Cys Ala Asp Leu Ser Asn Pro Thr Lys Ser Leu Glu Leu Tyr Arg			
390	395	400	
CAA TGG ACA GAC CGC ATC ATG GAG GAA TTT TTC CAG CAG GGA GAC AAA			1541
Gln Trp Thr Asp Arg Ile Met Glu Glu Phe Phe Gln Gln Gly Asp Lys			
405	410	415	420
GAG CGG GAG AGG GGA ATG GAA ATT AGC CCA ATG TGT GAT AAA CAC ACA			1589
Glu Arg Glu Arg Gly Met Glu Ile Ser Pro Met Cys Asp Lys His Thr			
425	430	435	
GCT TCT GTG GAA AAA TCC CAG GTT GGT TTC ATC GAC TAC ATT GTC CAT			1637
Ala Ser Val Glu Lys Ser Gln Val Gly Phe Ile Asp Tyr Ile Val His			
440	445	450	
CCA TTG TGG GAG ACA TGG GCA GAT TTG GTA CAG CCT GAT GCT CAG GAC			1685
Pro Leu Trp Glu Thr Trp Ala Asp Leu Val Gln Pro Asp Ala Gln Asp			
455	460	465	
ATT CTC GAT ACC TTA GAA GAT AAC AGG AAC TGG TAT CAG AGC ATG ATA			1733
Ile Leu Asp Thr Leu Glu Asp Asn Arg Asn Trp Tyr Gln Ser Met Ile			
470	475	480	

CCT CAA AGT CCC TCA CCA CCA CTG GAC GAG CAG AAC AGG GAC TGC CAG Pro Gln Ser Pro Ser Pro Pro Leu Asp Glu Gln Asn Arg Asp Cys Gln 485 490 495 500	1781
GGT CTG ATG GAG AAG TTT CAG TTT GAA CTG ACT CTC GAT GAG GAA GAT Gly Leu Met Glu Lys Phe Gln Phe Glu Leu Thr Leu Asp Glu Glu Asp 505 510 515	1829
TCT GAA GGA CCT GAG AAG GAG GGA GAG GGA CAC AGC TAT TTC AGC AGC Ser Glu Gly Pro Glu Lys Glu Gly Glu Gly His Ser Tyr Phe Ser Ser 520 525 530	1877
ACA AAG ACG CTT TGT GTG ATT GAT CCA GAA AAC AGA GAT TCC CTG GGA Thr Lys Thr Leu Cys Val Ile Asp Pro Glu Asn Arg Asp Ser Leu Gly 535 540 545	1925
GAG ACT GAC ATA GAC ATT GCA ACA GAA GAC AAG TCC CCC GTG GAT ACA Glu Thr Asp Ile Asp Ile Ala Thr Glu Asp Lys Ser Pro Val Asp Thr 550 555 560	1973
TAATCCCCCT CTCCCTGTGG AGATGAACAT TCTATCCTTG ATGAGCATGC CAGCTATGTG GTAGGGCCAG CCCACCATGG GGGCCAAGAC CTGCACAGGA CAAGGGCCAC CTGGCTTC GTTACTTGAG TTTGGAGTCA GAAAGCAAGA CCAGGAAGCA AATAGCAGCT CAGGAAATCC CACGGTTGAC TTGCTTGAT GGCAAGCTTG GTGGAGAGGG CTGAAGCTGT TGCTGGGGC CGATTCTGAT CAAGACACAT GGCTTGAAAA TGGAAGACAC AAAACTGAGA GATCATTCTG CACTAAGTTT CGGGAACCTTA TCCCCGACAG TGACTGAAC TCACTGACTAA TAACTTCATT TATGAATCTT CTCACTTGTC CCTTTGTCTG CCAACCTGTG TGCTTTTTT GTAAAACATT TTCATGTCTT TAAAATGCCT GTTGAATACC TGGAGTTAG TATCAACTTC TACACAGATA AGCTTTCAAA GTTGACAAAC TTTTTGACT CTTTCTGGAA AAGGGAAAGA AAATAGTCTT CCTTCTTTCT TGGGCAATAT CCTTCACTTT ACTACAGTTA CTTTGCAAA CAGACAGAAA GGATACACTT CTAACCCACAT TTTACTTCCT TCCCCGTGTG TCCAGTCCAA CTCCACAGTC ACTCTTAAAAA CTTCTCTCTG TTTGCCTGCC TCCAACAGTA CTTTTAACCTT TTTGCTGTAA ACAGAATAAA ATTGAACAAA TTAGGGGTA GAAAGGAGCA GTGGTGTGAG TCACCGTGAG AGTCTGCATA GAACTCAGCA GTGTGCCCTG CTGTTGCTTG GACCCCTGCC CCCACAGGAG TTGTACAGTC CCTGGCCCTG CTCCCTACCT CCTCTCTTCA CCCCCGTTAGG CTGTTTCAA TGTAATGCTG CCGTCCCTCT CTTGCACTGC CTTCTGCGCT AACACCTCCA TTCCCTGTTA TAACCGTGTAA TTTATTACTT AATGTATATA ATGTAATGTT TTGTAAGTTA TTAATTATA TATCTAACAT TGCCTGCCAA TGGTGGTGTAA AATTTGTGT AGAAAACCT GCCTAACAGT TACGACTTT TCTTGTAATG TTTGTATTG TGTATTATAT AACCCAAACG TCACTTAGTA GAGACATATG GCCCCCTTGG CAGAGAGGAC AGGGGTGGGC TTTTGTCAA AGGGTCTGCC CTTCCCTGC CTGAGTTGCT ACTTCTGCAC AACCCCTTA TGAACCAAGTT TTGGAAACAA TATTCTACAC ATTAGATACT AAATGGTTA TACTGAGCTT TTACTTTGT ATAGCTTGAT AGGGGCAGGG GGCAATGGAT GTAGTTTTA CCCAGGTTCT ATCCAAATCT ATGTGGGCAT	2033 2093 2153 2213 2273 2333 2393 2453 2513 2573 2633 2693 2753 2813 2873 2933 2993 3053 3113 3173 3233 3293 3353

GAGTTGGGTT ATAACCTGGAT CCTACTATCA TTGTGGCTTT GGTCAAAAG GAAACACTAC	3413
ATTTGCTCAC AGATGATTCT TCTGAATGCT CCCGAACTAC TGACTTGAA GAGGTAGCCT	3473
CCTGCCTGCC ATTAAGCAGG AATGTCATGT TCCAGTCAT TACAAAAGAA AACAAATAAAA	3533
CAATGTGAAT TTTTATAATA AAATGTGAAC TGATGTAGCA AATTACGAA ATGTGAAGCC	3593
TCTTCTGATA ACACCTGTTA GGCCCTTAC TGATGTCAGT TTCAGTTGT AAAATATGTT	3653
TCATGCTTTC AGTCAGCAT TGTGACTCAG TAAATACAGA AAATGGCACA AATGTGCATG	3713
ACCAATGTAT GTCTATGAAC ACTGCATTGT TTCAGGTGGA CATTATCG ATTTCAAAT	3773
GTTCACACA ATGTATGTTA TAGTGTATT ATTATATATT GTGTTCAAAT GCATTCTAAA	3833
GAGACTTTA TATGAGGTGA ATAAAGAAAA GCATAATTAA AAAAAAAA AAAAAAA	3890

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 564 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Lys Glu His Gly Gly Thr Phe Ser Ser Thr Gly Ile Ser Gly Gly	15
1 5 10 15	
Ser Gly Asp Ser Ala Met Asp Ser Leu Gln Pro Leu Gln Pro Asn Tyr	
20 25 30	
Met Pro Val Cys Leu Phe Ala Glu Glu Ser Tyr Gln Lys Leu Ala Met	
35 40 45	
Glu Thr Leu Glu Glu Leu Asp Trp Cys Leu Asp Gln Leu Glu Thr Ile	
50 55 60	
Gln Thr Tyr Arg Ser Val Ser Glu Met Ala Ser Asn Lys Phe Lys Arg	
65 70 75 80	
Met Leu Asn Arg Glu Leu Thr His Leu Ser Glu Met Ser Arg Ser Gly	
85 90 95	
Asn Gln Val Ser Glu Tyr Ile Ser Asn Thr Phe Leu Asp Lys Gln Asn	
100 105 110	
Asp Val Glu Ile Pro Ser Pro Thr Gln Lys Asp Arg Glu Lys Lys Lys	
115 120 125	
Lys Gln Gln Leu Met Thr Gln Ile Ser Gly Val Lys Lys Leu Met His	
130 135 140	
Ser Ser Ser Leu Asn Asn Thr Ser Ile Ser Arg Phe Gly Val Asn Thr	
145 150 155 160	
Glu Asn Glu Asp His Leu Ala Lys Glu Leu Glu Asp Leu Asn Lys Trp	
165 170 175	
Gly Leu Asn Ile Phe Asn Val Ala Gly Tyr Ser His Asn Arg Pro Leu	
180 185 190	

Thr Cys Ile Met Tyr Ala Ile Phe Gln Glu Arg Asp Leu Leu Lys Thr
195 200 205

Phe Arg Ile Ser Ser Asp Thr Phe Ile Thr Tyr Met Met Thr Leu Glu
210 215 220

Asp His Tyr His Ser Asp Val Ala Tyr His Asn Ser Leu His Ala Ala
225 230 235 240

Asp Val Ala Gln Ser Thr His Val Leu Leu Ser Thr Pro Ala Leu Asp
245 250 255

Ala Val Phe Thr Asp Leu Glu Ile Leu Ala Ala Ile Phe Ala Ala Ala
260 265 270

Ile His Asp Val Asp His Pro Gly Val Ser Asn Gln Phe Leu Ile Asn
275 280 285

Thr Asn Ser Glu Leu Ala Leu Met Tyr Asn Asp Glu Ser Val Leu Glu
290 295 300

Asn His His Leu Ala Val Gly Phe Lys Leu Leu Gln Glu Glu His Cys
305 310 315 320

Asp Ile Phe Met Asn Leu Thr Lys Lys Gln Arg Gln Thr Leu Arg Lys
325 330 335

Met Val Ile Asp Met Val Leu Ala Thr Asp Met Ser Lys His Met Ser
340 345 350

Leu Leu Ala Asp Leu Lys Thr Met Val Glu Thr Lys Lys Val Thr Ser
355 360 365

Ser Gly Val Leu Leu Leu Asp Asn Tyr Thr Asp Arg Ile Gln Val Leu
370 375 380

Arg Asn Met Val His Cys Ala Asp Leu Ser Asn Pro Thr Lys Ser Leu
385 390 395 400

Glu Leu Tyr Arg Gln Trp Thr Asp Arg Ile Met Glu Glu Phe Phe Gln
405 410 415

Gln Gly Asp Lys Glu Arg Glu Arg Gly Met Glu Ile Ser Pro Met Cys
420 425 430

Asp Lys His Thr Ala Ser Val Glu Lys Ser Gln Val Gly Phe Ile Asp
435 440 445

Tyr Ile Val His Pro Leu Trp Glu Thr Trp Ala Asp Leu Val Gln Pro
450 455 460

Asp Ala Gln Asp Ile Leu Asp Thr Leu Glu Asp Asn Arg Asn Trp Tyr
465 470 475 480

Gln Ser Met Ile Pro Gln Ser Pro Ser Pro Pro Leu Asp Glu Gln Asn
485 490 495

Arg Asp Cys Gln Gly Leu Met Glu Lys Phe Gln Phe Glu Leu Thr Leu
500 505 510

Asp Glu Glu Asp Ser Glu Gly Pro Glu Lys Glu Gly Glu Gly His Ser
515 520 525

Tyr Phe Ser Ser Thr Lys Thr Leu Cys Val Ile Asp Pro Glu Asn Arg
530 535 540

WO 94/20079

Asp	Ser	Leu	Gly	Glu	Thr	Asp	Ile	Asp	Ile	Ala	Thr	Glu	Asp	Lys	Ser
545															560
550															

Pro Val Asp Thr

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 40 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
 - (F) TISSUE TYPE: brain
- (ix) FEATURE:
 - (A) NAME/KEY: misc feature
 - (B) LOCATION: 1..40
 - (D) OTHER INFORMATION: /function= "5' PCR probe"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GGGGCTCGAG GAGGGACACA CGTATTCAG CAGCACAAAG

40

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 40 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (vi) ORIGINAL SOURCE:
 - (B) STRAIN: Homo sapiens
 - (F) TISSUE TYPE: brain
- (ix) FEATURE:
 - (A) NAME/KEY: misc feature
 - (B) LOCATION: 1..40
 - (D) OTHER INFORMATION: /function= "3' PCR probe"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CTCACTTGAG TGACTGATTA TTGAAGTAAA GAGCTCGGGG

40

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 42 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens
(F) TISSUE TYPE: brain

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1..42
(D) OTHER INFORMATION: /function= "5' PCR probe"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GGGGGCTCGA GAATGAAGGA GCACGGGGGC ACCTTCAGTA GC

42

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens
(F) TISSUE TYPE: Brain

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1..30
(D) OTHER INFORMATION: /function= "3' PCR probe"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GACGGTAAAAA ACGTCGACGG TAGGTACTGC

30

WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule encoding a human PDE IV_B.
2. The molecule according to Claim 1 wherein said nucleic acid is DNA.
- 5 3. The molecule according to Claim 2 having substantially the same sequence as Seq. ID. No. 1.
4. A human PDE IV_B substantially free of other proteins of human origin..
5. The protein according to Claim 4 having substantially the same amino acid sequence as Seq. ID. No. 2.
- 10 6. A vector comprising the nucleic acid of Claim 1.
7. The vector according to Claim 6 which is a plasmid.
8. The plasmid according to Claim 7 which is a cloning plasmid.
9. The plasmid according to Claim 7 which is an expression plasmid.
10. The plasmid of Claim 9 which is identified as p138NB/hb-PDE1.
- 15 11. A recombinant host cell comprising the vector of Claim 6.
12. The host cell according to Claim 11 which is a prokaryotic cell.
13. The host cell according to Claim 11 which is an eukaryotic cell.
14. The eukaryotic host cell according to Claim 13 which is a yeast.
15. A method for identifying ligands capable of binding to a
- 20 PDE IV_B enzyme comprising: contacting a PDE IV_B enzyme with a plurality of candidate ligands labeled with an analytically detectable reagent under conditions sufficient for ligand binding and identifying those ligand candidates capable of enzyme binding by detecting the presence of a labeled ligand/enzyme complex.
- 16 The method according to Claim 15 wherein the ligand is labeled with
- 25 radioactivity.
17. A method of screening compounds to identify those compounds which bind to a human PDE IV_B enzyme comprising contacting the enzyme with (a) a plurality of drug candidates in the presence of (b) an analytically detectable ligand known to bind to the enzyme, under conditions that permit binding of (a) and (b) to the enzyme, and identifying those candidate compounds capable of enhancing or inhibiting the binding or interaction of the known ligand with the enzyme.
- 30 18. The method according to Claim 17 wherein the known labeled ligand is selected from the group consisting of rolipram and cAMP.
19. The method according to Claim 18 wherein the label is a radioactive
- 35 label.
20. The method according to Claim 19 wherein the known labeled ligand is ³H-cAMP and the interaction detected is the catalytic conversion of the ligand.

21. A biological screening assay for the detection of PDE IV_B selective ligands comprising: (a) providing a PDE deficient host cell that exhibit a specific growth arrest phenotype associated with elevated cAMP levels; (b) transforming or transfecting said host cell with the plasmid of Claim 9 and culturing the resultant recombinant host cell under conditions sufficient for the expression of PDE IV_B enzyme and sufficient to generate a growth arrest response should the expressed PDE IV_B enzyme be inhibited; (c) contacting the recombinant host cell with a plurality of candidate compounds and (d) identifying those compounds which are capable of inhibiting the enzyme and thereby unmasking the growth arrest phenotype.

10 22. The method according to Claim 21 wherein said host cell is a yeast cell and said plasmid is p138NB/hb-PDE1.

23. The method according to Claim 22 wherein said specific growth arrest phenotype is selected from the group consisting of sensitivity to nitrogen starvation, heat shock sensitivity and inability to grow on suboptimal carbon sources.

15 24. A pharmaceutical composition comprising a compound identified by the method of Claim 21 and a pharmaceutically acceptable carrier.

25. An antisense oligonucleotide having sequence capable of binding specifically with any sequence of an mRNA molecule which encodes the human PDE IV_B having the amino acid sequence of Seq. ID No 2 so as to prevent the translation thereof.

20 26. An antibody directed to the human PDE IV_B of Claim 5.

27. The antibody according to Claim 26 which is a monoclonal antibody.

28. A fusion protein comprising a PDE IV_B domain and an cell surface localizing domain.

25 29. A method of screening compounds to identify those compounds which bind to a human PDE IV_B enzyme comprising contacting recombinant host cells expressing on the surface thereof the fusion protein of Claim 29 with a plurality of drug candidates, under conditions to permit binding to the PDE IV_B domain, and identifying those candidate drugs capable of enhancing or inhibiting the catalytic activity of the enzyme.

GGCACGAGCC	TAAGAACCT	CGGGATGACT	AAGGCAGAGA	GAGTCTGAGA	AAACTCTTIG	60
GTGCTTCTGC	CTTAGTTT	AGGACACATT	TATGCAGATG	AGCTTATAAG	AGACGCTTCC	120
CTCCGCCTTC	TTCTCAGAG	GAAGTTCTT	GGTAGATCAG	GCACACCTCA	TCCAGGGGG	180
GGGTTGGGG	GAACACTTGGC	ACCAGGCCATC	CCAGGCAGAG	CACCACTGTG	ATTGTGTTCTC	240
CTGGTGGAGA	GAGCTGGAG	GAAGGAGCCA	GGGTGCAAAAT	AATG AAG GAG CAC	Met Lys Glu His	293
1						
GGG GGC ACC TTC AGT AGC ACC GGA ATC AGC GGT GGT GAC TCT						341
Gly Gly Thr Phe Ser Ser Thr Gly Ile Ser Gly Gly Ser Asp Ser						
5			15			20
GCT ATG GAC AGC CTG CAG CCG CTC CAG CCT AAC TAC ATG CCT GTG TGT						389
Ala Met Asp Ser Leu Gln Pro Leu Gln Pro Asn Tyr Met Pro Val Cys						
10			30			35
TTG TTT GCA GAA TCT TAT CAA AAA TTA GCA ATG GAA ACG CTG GAG						437
Leu Phe Ala Glu Glu Ser Tyr Gln Lys Leu Ala Met Glu Thr Leu Glu						
40			45			50
GAA TTA GAC TGG TGT TTA GAC CAG CTA GAG ACC ATA CAG ACC TAC CGG						485
Glu Leu Asp Asp Trp Cys Leu Asp Gln Leu Glu Thr Ile Gln Thr Tyr Arg						
55			60			65

TCT	GTC	AGT	GAG	ATG	GCT	TCT	AAC	AAG	TTC	AAA	AGA	ATG	CTG	AAC	CGG	533
Ser	Val	Ser	Glu	Met	Ala	Ser	Asn	Lys	Phe	Lys	Arg	Met	Leu	Asn	Arg	
70																
GAG	CTG	ACA	CAC	CTC	TCA	GAG	ATG	AGC	CGA	TCA	GGG	AAC	CAG	GTG	TCT	581
Glu	Leu	Thr	His	Leu	Ser	Glu	Met	Ser	Arg	Ser	Gly	Asn	Gln	Val	Ser	
85																
GAA	TAC	ATT	TCA	AAT	ACT	TTC	TTA	GAC	AAG	CAG	AAT	GAT	GTG	GAG	ATC	629
Glu	Tyr	Ile	Ser	Asn	Thr	Phe	Leu	Asp	Lys	Gln	Asn	Asp	Val	Glu	Ile	
CCA	TCT	CCT	ACC	CAG	AAA	GAC	AGG	GAG	AAA	AAG	AAA	AAG	CAG	CAG	CTC	677
Pro	Ser	Pro	Thr	Gln	Lys	Asp	Arg	Glu	Lys	Lys	Lys	Lys	Gln	Gln	Leu	
ATG	ACC	CAG	ATA	AGT	GGA	GTG	AAG	AAA	TTA	ATG	CAT	AGT	TCA	AGC	CTA	725
Met	Thr	Gln	Ile	Ser	Gly	Val	Lys	Lys	Leu	Met	His	Ser	Ser	Ser	Leu	
AAC	AAT	ACA	AGC	ATC	TCA	CGC	TTT	GGA	GTC	AAC	ACT	GAA	AAT	GAA	GAT	773
Asn	Asn	Thr	Ser	Ile	Ser	Arg	Phe	Gly	Val	Asn	Thr	Glu	Asn	Glu	Asp	
CAC	CTG	GCC	AAG	GAG	CTG	GAA	GAC	CTG	AAC	AAA	TGG	GGT	CTT	AAC	ATC	821
His	Leu	Ala	Lys	Glu	Leu	Glu	Asp	Leu	Asn	Lys	Trp	Gly	Leu	Asn	Ile	
165																

2 / 11

SUBSTITUTE SHEET (RULE 26)

FIGURE 1 (B)

TTT	AAT	GTG	GCT	GGA	TAT	TCT	CAC	AAT	AGA	CCC	CTA	ACA	TGC	ATC	ATG	869
Phe	Asn	Val	Ala	Gly	Tyr	Ser	His	Asn	Arg	Pro	Leu	Thr	Cys	Ile	Met	
															195	
TAT	GCT	ATA	TTC	CAG	GAA	GAC	CTC	CTA	AAG	ACA	TTC	AGA	ATC	TCA	917	
Tyr	Ala	Ile	Phe	Gln	Glu	Arg	Asp	Leu	Leu	Lys	Thr	Phe	Arg	Ile	Ser	
															210	
TCT	GAC	ACA	TTT	ATA	ACC	TAC	ATG	ACT	TTA	GAA	GAC	CAT	TAC	CAT	965	
Ser	Asp	Thr	Phe	Ile	Thr	Tyr	Met	Met	Thr	Leu	Glu	Asp	His	Tyr	His	
															225	
TCT	GAC	GTG	GCA	TAT	CAC	AAC	AGC	CTG	CAC	GCT	GAT	GTA	GCC	CAG	1013	
Ser	Asp	Val	Ala	Tyr	His	Asn	Ser	Leu	His	Ala	Ala	Asp	Val	Ala	Gln	
															240	
TCG	ACC	CAT	GTT	CTC	CTT	TCT	ACA	CCA	GCA	TTA	GAC	GCT	GTC	TTC	ACA	1061
Ser	Thr	His	Val	Leu	Leu	Ser	Thr	Pro	Ala	Leu	Asp	Ala	Val	Phe	Thr	
															260	
GAT	TTG	GAG	ATC	CTG	GCT	GCC	ATT	TTT	GCA	GCT	GCC	ATC	CAT	GAC	GTT	1109
Asp	Leu	Glu	Ile	Leu	Ala	Ala	Ile	Phe	Ala	Ala	Ala	Ile	His	Asp	Val	
															275	
GAT	CAT	CCT	GGA	GTC	TCC	AAT	CAG	TTT	CTC	ATC	AAC	ACA	AAT	TCA	GAA	1157
Asp	His	Pro	Gly	Val	Ser	Asn	Gln	Phe	Leu	Ile	Asn	Thr	Asn	Ser	Glu	
															285	
															290	

CTT	GCT	TTG	ATG	TAT	AAT	GAT	GAA	TCT	GTG	TTG	GAA	AAT	CAT	CAC	CTT	1205
Leu	Ala	Ieu	Met	Tyr	Asn	Asp	Glu	Ser	Val	Ieu	Glu	Asn	His	His	Leu	
295							300								305	
GCT	GTT	GGT	TTC	AAA	CTG	CTG	CAA	GAA	CAC	TGT	GAC	ATC	TTG	ATG		1253
Ala	Val	Gly	Phe	Lys	Leu	Leu	Gln	Glu	Glu	His	Cys	Asp	Ile	Phe	Met	
310							315								320	
AAT	CTC	ACC	AAG	AAG	CAG	CGT	CAG	ACA	CTC	AGG	AAG	ATG	GTT	ATT	GAC	1301
Asn	Leu	Leu	Thr	Lys	Gln	Arg	Gln	Thr	Leu	Arg	Lys	Met	Val	Ile	Asp	
325							330								340	
ATG	GTG	TTA	GCA	ACT	GAT	ATG	TCT	AAA	CAT	ATG	AGC	CTG	CTG	GCA	GAC	1349
Met	Val	Leu	Ala	Thr	Asp	Met	Ser	Lys	His	Met	Ser	Leu	Leu	Ala	Asp	
345							350								355	
CTG	AAG	ACA	ATG	GTA	GAA	ACG	AAG	AAA	GTT	ACA	AGT	TCA	GGC	GTT	CTT	1397
Leu	Lys	Thr	Met	Val	Glu	Thr	Lys	Lys	Val	Thr	Ser	Ser	Gly	Val	Leu	
360							365								370	
CTC	CTA	GAC	AAC	TAT	ACC	GAT	CGC	ATT	CAG	GTC	CTT	CGC	AAC	ATG	GTA	1445
Leu	Leu	Asp	Asn	Tyr	Thr	Asp	Arg	Ile	Gln	Val	Leu	Arg	Asn	Met	Val	
375							380								385	
CAC	TGT	GCA	GAC	CTG	AGC	AAC	CCC	ACC	AAG	TCC	TTG	GAA	TTG	TAT	CGG	1493
Cys		Ala	Asp	Leu	Ser	Asn	Pro	Thr	Lys	Ser	Leu	Glu	Leu	Tyr	Arg	
390							395								400	

CAA TGG ACA GAC CGC ATC ATG GAG GAA TTT TTC CAG CAG GGA GAC AAA	1541	
Gln Trp Thr Asp Arg Ile Met Glu Glu Phe Phe Gln Gln Gly Asp Lys		
405	420	
GAG CGG GAG AGG GGA ATG GAA ATT AGC CCA ATG TGT GAT AAA CAC ACA	1589	
Glu Arg Glu Arg Gly Met Glu Ile Ser Pro Met Cys Asp Lys His Thr		
425	435	
GCT TCT GTG GAA AAA TCC CAG GTT TTC ATC GAC TAC ATT GTC CAT	1637	
Ala Ser Val Glu Lys Ser Gln Val Gly Phe Ile Asp Tyr Ile Val His		
440	450	
CCA TTG TGG GAG ACA TGG GCA GAT TTG GTA CAG CCT GAT GCT CAG GAC	1685	
Pro Leu Trp Glu Thr Trp Ala Asp Leu Val Gln Pro Asp Ala Gln Asp		
455	465	
ATT CTC GAT ACC TTA GAA GAT AAC AGG AAC TGG TAT CAG AGC ATG ATA	1733	
Ile Leu Asp Thr Leu Glu Asp Asn Arg Asn Trp Tyr Gln Ser Met Ile		
470	480	
CCT CAA AGT CCC TCA CCA CCA CTG GAC GAG CAG AAC AGG GAC TGC CAG	1781	
Pro Gln Ser Pro Ser Pro Leu Asp Glu Gln Asn Arg Asp Cys Gln		
485	495	500
GGT CTG ATG GAG AAG TTT CAG TTT GAA CTG ACT CTC GAT GAG GAA GAT	1829	
Gly Leu Met Glu Lys Phe Gln Phe Glu Leu Thr Leu Asp Glu Glu Asp		
505	510	

TCT	GAA	GGA	CCT	GAG	AAG	GAG	GGA	GAG	GGA	CAC	AGC	TAT	TTC	AGC	AGC	1877	
Ser	Glu	Gly	Pro	Glu	Lys	Glu	Gly	Glu	Gly	His	Ser	Tyr	Phe	Ser	Ser		
																530	
																520	
ACA	AAG	ACG	CTT	TGT	TGT	ATT	GAT	CCA	GAA	AAC	AGA	GAT	TCC	CTG	GGA	1925	
Thr	Lys	Thr	Leu	Cys	Val	Ile	Asp	Pro	Glu	Asn	Arg	Asp	Ser	Leu	Gly		
																545	
																535	
GAG	ACT	GAC	ATA	GAC	ATT	GCA	ACA	GAA	GAC	AAG	TCC	CCC	GTG	GAT	ACA	1973	
Glu	Thr	Asp	Ile	Asp	Ile	Ala	Thr	Glu	Asp	Lys	Ser	Pro	Val	Asp	Thr		
																560	
																550	
TATCCCCCT	CTCCCTGTGG	AGATGAACAT	TCTATCCTTG	ATGAGCATGC	CAGCTATGTG												2033
GTAGGGCCAG	CCCACTGG	GGGCCAAGAC	CTGGCACAGGA	CAAGGGCCAC	CTGGCTTTCA												2093
GTIACTTGTAG	TTGGAGTCA	GAAGGCAAGA	CCAGGAAGCA	ATAGGAGCT	CAGGAAATCC												2153
CACGGTTGAC	TTGCCTTGAT	GGCAAGCTTG	GTGGAGAGGG	CTGAAGCTGT	TGCTGGGGC												2213
CGATTCTGAT	CAAGACACAT	GGCTTGAAA	TGGAAGACAC	AAAACTGAGA	GATCATCTG												2273
CACTAAGTT	CGGGAACTTA	TCCCCGACAG	TGACTGAACT	CACTGACTAA	TAACCTCAT												2333
TATGAATCTT	CTCACTTGTC	CCTTTGTCTG	CCAACCTGTG	TGCCTTTTT	GTAAACATT												2393
TTCATGTCTT	AAAATGCCT	GTGAAATACC	TGGAGTTAG	TATCAACTTC	TACACAGATA												2453

AGCTTTCAA	GTTGACAAAC	TTTTTGACT	CTTTCTGGAA	AAGGAAAGA	AAATAGTCCT	2513
CCTTCTTCT	TGGCAATAT	CCCTCACTTT	ACTACAGTTA	CTTTTGCAAA	CAGACAGAAA	2573
GGATACACCT	CTAACACAT	TTTACTTCCT	TCCCTGTG	TCAGTCCAA	CTCCACAGTC	2633
ACTCTAAA	CTTCTCTCTG	TTGCCTGCC	TCCAACAGTA	CTTTAACTT	TTTGCTGTAA	2693
ACAGAATAAA	ATTGAACAAA	TTAGGGGTA	GAAGGAGCA	GTGGTGTGCGT	TCACCGGTGAG	2753
AGTCTGCATA	GAACTCAGCA	GTGTCCTG	CTGTCCTTG	GACCCCTGCC	CCCACAGGAG	2813
TTGTACAGTC	CCTGGCCCTG	CTCCCTACCT	CCTCTCTCA	CCCCGTAGG	CTGTTTCAA	2873
TGTAATGCTG	CCGCCCTCT	CTTGCACTGC	CTTCTGGCT	AACACCTCCA	TTCCTGTTA	2933
TAACCGTGTAA	TTTATTACCT	ATGTATATA	ATGTAATGTT	TTGTAAGTTA	TTAATTATA	2993
TATCTAACAT	TGCTGCCAA	TGGTGGTGT	AAATTGGTGT	AGAAAACCTCT	GCCTAACAGT	3053
TACGACTTT	TCTTGTAAATG	TTTTGTATTG	TGTATTATAT	AACCCAAACG	TCACTTAGTA	3113
GAGACATATG	GCCCCCTTGG	CAGAGAGGAC	AGGGGTGGGC	TTTTGTTCAA	AGGGTCTGCC	3173
CTTCCCTTGC	CTGAGTTGCT	ACTTCTGCAC	AACCCCTTAA	TGAACCAAGTT	TTGGAAACAA	3233
TATTCTACAC	ATTAGATACT	AAATGGTTA	TACTGAGCTT	TTACTTTGT	ATAGCTGTGAT	3293

AGGGGCAGGG GGCATGGAT GTAGTTTTA CCCAGGTCT ATCCAAATCT ATGTGGGCAT 3353
GAGTTGGTT ATAACTGGAT CCTACTATCA TTGTTGGCTT GGTTCAAAAG GAAACACTAC 3413
ATTGCTCAC AGATGATTCT TCTGAATGCT CCCGAACTAC TGACTTTGAA GAGGTTAGCCT 3473
CCTGCCTGCC ATTAAGCAGG AATGTCAATGT TCCAGTTCAT TACAAAGAA ACAAATAAA 3533
CAATGTGAAT TTTATAATA AAATGTGAAC TGATGTAGCA ATTACGCAA ATGTGAAGCC 3593
TCTTCTGATA ACACCTGTTA GGCCTCTTAC TGATGTCACT TTCAGTTGT AAAATAATGTT 3653
TCATGCTTC AGTTCAAGCAT TTGACTCAG TAAATAACAGA AAATGGCACA AATGTGCATG 3713
ACCAATGTAT GTCTATGAAC ACTGCATTGT TTCAGGGTA CATTTTATCG ATTTCAAAT 3773
GTTTCTCACA ATGTATGTTA TAGTGTATT ATTATATATT GTGTTCAAAAT GCATTCTAAA 3833
GAGACTTTA TATGAGGTGA ATAAAGAAA GCATAATAA AAAAATAAA AAAAAAA 3890

FIGURE 1 (H)

RU/US 16 MAY 1994




FIGURE 3




FIGURE 4




Figure 5

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/02612

A. CLASSIFICATION OF SUBJECT MATTER

IPC(S) :Please See Extra Sheet.

US CL : 435/19, 196, 240.1, 252.3, 255.1, 320.1; 514/2 ; 530/387.9, 388.26 ; 536/23.2

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/19, 196, 240.1, 252.3, 255.1, 255.2, 320.1; 514/2; 530/387.1, 387.9, 388.26; 536/23.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Gene, Volume 129, issued 1993, R. OBERNOLTE et al., "The cDNA of a human lymphocyte cyclic-AMP phosphodiesterase (PDE IV) reveals a multigene family", pages 239-247, entire document	1-9, 11-12, 25
---		-----
Y		10, 13-14, 26-28
X,P	Molecular and Cellular Biology, Volume 13, No. 10, issued October 1993, G. BOLGER et al., "A Family of Human Phosphodiesterases Homologous to the <i>dunce</i> Learning and Memory Gene Product of <i>Drosophila melanogaster</i> Are Potential Targets for Antidepressant Drugs", pages 6558-6571, entire document.	1-9, 11, 13-14, 25
---		-----
Y		10, 12, 15-24, 26-29

 Further documents are listed in the continuation of Box C.

See patent family annex.

• Special categories of cited documents:	
A document defining the general state of the art which is not considered to be part of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
E earlier document published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O document referring to an oral disclosure, use, exhibition or other means	*&* document member of the same patent family
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

08 JUNE 1994

Date of mailing of the international search report

JUN 17 1994

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703)Authorized officer
GABRIELE BUGAISKY
Telephone No. (703) 308-0196

Form PCT/ISA/2105 (33rd sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/02612

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	Journal of Biological Chemistry, Volume 268, No. 9, issued 25 March 1993, M. M. McLAUGHLIN et al., "A Low Km, Rolipram-sensitive, cAMP-specific Phosphodiesterase from Human Brain", pages 6470-6476, entire document.	1-9, 11-16, 25
--		-----
Y		17-24, 26-29
X	WO,A, 91/16457, (WIGLER ET AL.,) 31 October 1991, see pages 8-9, 11-13, 15-20, 31-34, 43-53, 91-99, claims 15-20.	1-9, 11-16, 25
--		-----
Y		10, 17-24, 26-29
Y	US,A, 5,190,931, (M. INOUYE), 02 March 1993, entire document.	25
Y	W.D. ODELL ET AL. (eds.), "PRINCIPLES OF COMPETITIVE PROTEIN BINDING ASSAYS" published 1983, by JOHN WILEY & SONS (N.Y.), pages 243-254, see entire document.	17-23, 29
Y	METHODS IN ENZYMOLOGY, Volume 70, issued 1980, P. M. MAURER et al., "Proteins and polypeptides as antigens", pages 49-52.	26-27
Y	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, USA, Volume 83, issued November 1986, J. R. MURPHY et al., "Genetic construction, expression and melanoma-selective cytotoxicity of a diphtheria toxin-related α -melanocyte-stimulating hormone fusion protein", pages 8258-8262, see entire document.	28-29
X	BRITISH JOURNAL OF PHARMACOLOGY, Volume 103, issued 1991, G. DENT et al., "Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by 'type-IV'-selective PDE inhibitors", pages 1339-1346, entire document.	24

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/02612

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Telephone Practice
Please See Extra Sheet.

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

**IMAGES ARE BEST AVAILABLE COPY.
As rescanning these documents will not correct the image
problems checked, please do not report these problems to
the IFW Image Problem Mailbox.**